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Abstract 
Bibek Parajuli 
 
IDENTIFICATION, KINETIC AND STRUCTURAL CHARACTERIZATION OF 
SMALL MOLECULE INHIBITORS OF ALDEHYDE DEHYDROGENASE 3A1 
(ALDH3A1) AS AN ADJUVANT THERAPY FOR REVERSING CANCER CHEMO-
RESISTANCE 
 
ALDH isoenzymes are known to impact the sensitivity of certain neoplastic cells 
toward cyclophosphamides and its analogs. Despite its bone marrow toxicity, cyclophos-
phamide is still used to treat various recalcitrant forms of cancer. When activated, cyclo-
phosphamide forms aldophosphamide that can spontaneously form the toxic phospho-
ramide mustard, an alkylating agent unless detoxified by ALDH isozymes to the carbox-
yphosphamide metabolite. Prior work has demonstrated that the ALDH1A1 and 
ALDH3A1 isoenzymes can convert aldophosphamide to carboxyphosphamide. This has 
also been verified by over expression and siRNA knockdown studies. Selective small 
molecule inhibitors for these ALDH isoenzymes are not currently available. We hypothe-
sized that novel and selective small molecule inhibitors of ALDH3A1 would enhance 
cancer cells’ sensitivity toward cyclophosphamide. If successful, this approach can widen 
the therapeutic treatment window for cyclophosphamides; permitting lower effective dos-
ing regimens with reduced toxicity. An esterase based absorbance assay was optimized in 
a high throughput setting and 101, 000 compounds were screened and two new selective 
inhibitors for ALDH3A1, which have IC50 values of 0.2 µM (CB7) and 16 µM (CB29) 
vii 
 
were discovered. These two compounds compete for aldehyde binding, which was vali-
dated both by kinetic and crystallographic studies. Structure activity relationship dataset 
has helped us determine the basis of potency and selectivity of these compounds towards 
ALDH3A1 activity. Our data is further supported by mafosfamide (an analog of cyclo-
phosphamide) chemosensitivity data, performed on lung adenocarcinoma (A549) and gli-
oblastoma (SF767) cell lines. Overall, I have identified two compounds, which inhibit 
ALDH3A1’s dehydrogenase activity selectively and increases sensitization of ALDH3A1 
positive cells to aldophosphamide and its analogs. This may have the potential in improv-
ing chemotherapeutic efficacy of cyclophosphamide as well as to help us understand bet-
ter the role of ALDH3A1 in cells. Future work will focus on testing these compounds on 
other cancer cell lines that involve ALDH3A1 expression as a mode of chemoresistance.  
 
 
Thomas D. Hurley Ph.D., Chair 
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I. Introduction 
A. Overview 
1.  Aldehydes: Sources, reactivity and metabolism 
Aldehydes are highly reactive compounds that are produced as a consequence of 
many exogenous and endogenous processes. Endogenous sources of aldehydes include 
lipid peroxidation products and metabolites of neurotransmitters and amino acids. Over 
200 aldehyde species are generated from the oxidative degradation of cellular membrane 
lipids, also known as lipid peroxidation products such as 4–hydroxynonenal and 
malondialdehyde (Esterbauer et al., 1991). Amino acid catabolism generates several al-
dehyde intermediates, including glutamate γ–semialdehyde, while neurotransmitters, such 
as gamma–aminobutyric acid (GABA), serotonin, noradrenaline, adrenaline, and dopa-
mine, also give rise to aldehyde metabolites during oxidative deamination (Vasiliou et al., 
2004; Marchitti et al., 2007). Exogenous sources include food, ethanol which generates 
acetaldehyde, nicotine and cyclophosphamide metabolites (Lindahl, 1992). Various alde-
hydes, including formaldehyde, acetaldehyde and acrolein, are also ubiquitous in the en-
vironment and are present in smog, cigarette smoke and motor vehicle exhaust. Alde-
hydes are also produced in various industries in the production of resins, polyester plas-
tics. Numerous dietary aldehydes, including citral and benzaldehyde, are approved addi-
tives in various foods where they provide flavor and odor (Marchitti et al., 2008). Table 1 
shows the list of aldehydes generated from various endogenous and exogenous sources.  
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Table 1. Aldehydes and its sources. Aldehydes generated from various exogenous and 
endogenous sources via metabolism of amino acids, fatty acids and ethanol (Extracted 
from Lindahl, 1992). 
Endogenous source Aldehyde 
Choline metabolism Betaine aldehyde 
Corticosteroid catabo-
lism 
21–Dihydrocorticosteroids 
Dopamine catabolism 3, 4–Dihydroxyphenylacetaldehyde 
GABA metabolism Succinic semialdehyde 
Lipid peroxidation 
Malondialdehyde, 4–Hydroxynonenal, Hex-
anal 
Proline biosynthesis Glutamic–γ–semialdehyde 
Putrescine catabolism γ–amino butyraldehyde 
Serotonin metabolism 5–Hydroxyindoleacetaldehyde 
Threonine catabolism Acetaldehyde 
Vitamin A metabolism Retinal 
      
Exogenous source Aldehyde 
Codeine Formaldehyde 
Combustion Formaldehyde, acetaldehyde, acrolein 
Cyclophosphamide Aldophosphamide, acrolein 
Ethanol Acetaldehyde 
Foods Benzaldehyde, lipid aldehydes, acrolein,  
 
glyoxal, methylglyoxal, crotonaldehyde 
Nicotine γ–3–Pyridyl–γ–methylaminobutyraldehyde 
 
 While some aldehydes play important roles in normal physiological processes in-
cluding vision, embryonic development and neurotransmission, many aldehydes are car-
cinogenic and cytotoxic (Yokoyama et al., 2001). Aldehydes show high reactivity due to 
their highly reactive carbonyl group. Unlike free radicals, aldehydes are relatively long 
lived and not only react with cellular components near the site of their formation, but also 
affect targets some distance away as a consequence of diffusion or transport (Esterbauer 
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et al., 1991). They show a strong tendency to form adducts with nucleic acids, glutathione 
(GSH) and proteins leading to impaired cellular homeostasis, enzyme inactivation, DNA 
damage and cell death. If their levels are not minimized, aldehydes cause damage that can 
cause cancer and several other complications (Lindahl, 1992).  
In order to minimize the amount of aldehyde in the body, several mechanisms of 
elimination exist. Aldehydes are detoxified primarily through reductive and oxidative 
Phase I enzyme–catalyzed reactions (Figure 1), including the non–P450 enzyme systems 
alcohol dehydrogenase (ADH), aldo–keto reductase (AKR), short chain dehydrogenase/ 
reductase (SDR), aldehyde oxidase (AOX), and aldehyde dehydrogenase (ALDH).  
 
Figure 1. Enzymes involved in aldehyde detoxication and their mechanisms. Figure 
shows reaction mechanism of four classes of enzymes that metabolize aldehydes and ke-
tones. 
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The aldo–keto reductase superfamily reversibly reduces a variety of aldehydes 
and ketones to their corresponding alcohols. The conversion, however, strongly depends 
on the NADPH/ NADP
+
 ratio. Aldehyde reductase shows broad specificity and prefers 
negatively charged aldehydes (Jez et al., 1997). It has also been involved in various dis-
eased states such as diabetes (Lee et al., 1995; Suzen and Buyukbingol, 2003), lung can-
cer (Fukumoto et al., 2005), abnormal metabolism of male and female sex hormones 
(Penning and Byrns, 2009) and bile acid deficiency (Lemonde at al., 2003). Alcohol de-
hydrogenases catalyze the oxidation of alcohols to aldehydes and ketones, but can also 
catalyze the reverse reaction. The direction of the reaction, however, strongly depends on 
the NAD
+
/ NADH ratio (McMahon, 1982). Aldehyde oxidase on the other hand catalyzes 
the oxidation of aldehydes into carboxylic acid. It also catalyzes the hydroxylation of 
some heterocycles and aromatic aldehydes that arise from metabolism of biogenic amines 
(Beedham et al., 1995). Similarly, another enzyme, glutathione S–transferase, is known 
to be important for elimination of lipid peroxidation products via conjugation to glutathi-
one (Srivastava et al., 1998). The role of these enzymes in aldehyde metabolism is rela-
tively small compared to that of aldehyde dehydrogenase.  
Aldehyde dehydrogenases are NAD(P)
+
 dependent enzymes that catalyze the ir-
reversible oxidation of a broad range of aliphatic and aromatic aldehydes generated from 
various exogenous and endogenous precursors to their corresponding carboxylic acids 
(Lindahl, 1992; Vasiliou et al., 2000). The human genome contains 19 members of the 
ALDH superfamily where each member exhibits unique chromosomal locations 
(Vasiliou et al., 2005) (Table 2). A nomenclature system based on divergent evolution 
and amino acid identity was established for the ALDH superfamily over 12 years ago and 
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is based on the P450 nomenclature system (Vasiliou et al., 1999). ALDH isozymes are 
found in all cellular compartments including cytosol, mitochondria, endoplasmic reticu-
lum and nucleus, with several found in more than one compartment. ALDH isozymes 
found in organelles other than the cytosol possess leader or signal sequences that allow 
their translocation to specific subcellular regions (Braun et al., 1987). After translocation 
or import, these leader sequences may be removed. Mutations and polymorphisms in 
ALDH genes are associated with distinct phenotypes in humans and rodents (Vasiliou et. 
al., 2000). These include Sjögren–Larsson syndrome (Rizzo et al., 2005), type II hy-
perprolinemia (Onenli–Mungan et al., 2004), γ–hydroxybutyric aciduria (Akaboshi et al., 
2003), pyridoxine–dependent seizures (Mills et al., 2006), hyperammonemia 
(Baumgartner et al., 2000), alcohol–related diseases (Enomoto et al., 1991), cancer 
(Yokoyama et al., 2001) and late onset of Alzheimer’s disease (Kamino et al., 2000). In 
addition to clinical phenotypes, studies on transgenic knockout mice have suggested a 
pivotal role of ALDHs in physiological functions and processes such as embryogenesis 
and development as well (Niederreither et al., 1999; Dupe et al., 2003).  
Besides aldehyde detoxication, ALDHs are also able to catalyze ester hydrolysis 
(Sydow et al., 2004) and can act as binding proteins for various endogenous (e.g., andro-
gen, cholesterol and thyroid hormone) and exogenous compounds (acetaminophen) 
(Vasiliou et al., 2004). ALDH enzymes also have important antioxidant roles including 
the production of NAD(P)H (Pappa et al., 2003; Lassen et al., 2006), the absorption of 
UV light (Estey et al., 2007; Lassen et al., 2007). 
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Table 2. ALDH genes, their loci, localization, PDB ID, substrates and phenotypes. 
 
New name ALDH1L1 ALDH2 ALDH3A1 
Common  10FTDH ALDH2 ALDH3 
name       
Chr. Loc. 3q21.2 12q24.2 17p11.2 
Tissue  cytoplasm liver, various cornea, lung 
location   tissues, stomach, liver 
    mitochondria   
Substrates folate acetaldehyde  
aromatic  
aldehydes 
  metabolism   
lipid peroxidation 
products 
Comments KO mice Alcoholism, cocaine KO mice have 
  
infertile, 
less addiction, myocardial cataracts, CP 
  folate infarction metabolism 
Oligomer Unknown Tetramer Dimer 
PDB ID NA 1O02 3SZA 
 
 
New name ALDH1A1 ALDH1A2 ALDH1A3 ALDH1B1 
Common  ALDH1A1 RALDHII ALDH6 ALDH5 
name     RALDHIII   
Chr. Loc. 9q21.13 15q22.1 15q26.3 9p11.1 
Tissue  ubiquitous embryonic stomach, liver, kidney 
location   trunk, kidney, muscle 
    forebrain saliva heart 
Substrates 
aliphatic alde-
hyde, retinal 
Aliphatic 
aldehyde 
Aliphatic 
aldehyde 
  retinal, CP   retinal acetaldehyde 
Comments Inducible KO mice die  KO mice Unknown 
  KO mice have 
shortly after 
birth lethal   
  cataracts       
Oligomer tetramer tetramer tetramer Tetramer 
PDB ID 1BXS (sheep) 1BI9 (rat) NA NA 
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Information extracted from www.aldh.org 
New name ALDH3A2 ALDH3B1 ALDH3B2 ALDH4A1 
Common  FALDH ALDH7 ALDH8 GGSDH, ALDH4 
name ALDH10     P5CDH 
Chr. Loc. 17p11.2 11q13.2 11q13.2 1p36.13 
Tissue  liver, heart kidney, lungs, parotid 
liver, kidney, mi-
tochondria 
location muscle (ER) microsome microsomal skeletal muscle, 
          
Substrates 
fatty aldehyde, 
aromatic aliphatic, Unknown 
gamma–
semialdehyde 
  membrane lipid aromatic     
Comments Sjogren Larsson Linked to Unknown Type II 
  syndrome schizophrenia   hyperprolinemia 
          
Oligomer dimer dimer NA dimer 
PDB ID NA NA NA 102O 
 
New name ALDH5A1 ALDH6A1 ALDH7A1 ALDH9A1 
Common  SSDH MMSDH ANTQ1 ALDH9 
name         
Chr. Loc. 6p22.2 14q24.3 5q31 1q23.1 
Tissue  brain, liver kidney, liver, 
cochlea, ova-
ry 
liver, kid-
ney 
location heart, heart, 
eye, heart, 
liver 
brain, mus-
cle, 
  mitochondria mitochondria kidney cytoplasm 
Substrates succinic Methylmalonate   GABA 
  semialdehyde semialdehyde     
Comments gamma– developmental pyridoxine    
  hydroxybutyric delay dependent   
  aciduria   seizures   
Oligomer tetramer tetramer   tetramer 
PDB ID NA     1A4S  
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ALDH enzymes share a large number of highly conserved residues necessary for 
catalysis and cofactor binding. Sequence alignment of 145 ALDHs demonstrates a very 
limited number of conserved residues. The catalytic cysteine Cys302, Glu268, Gly299 
and Asn169 are all essential for catalysis (numbering based on the mature human 
ALDH2 protein) (Steinmetz et al., 1997; Liu et al., 1997; Hempel et al., 1997; Perozich et 
al., 2001). Gly245 and Gly250 are essential residues within the ALDH Rossman fold 
(GxxxxG) and are necessary for cofactor binding. Also, residues Lys192, Glu399 and 
Phe401 are important for proper cofactor positioning and, thus, impact catalysis. Crystal 
structures of mammalian ALDH enzymes have shown that each subunit has a NAD(P)
+ 
binding domain, a catalytic domain and an oligomerization domain (Steinmetz et al., 
1997; Liu et al., 1997).  
Crystallographic structures have also helped us understand the basic catalytic 
mechanism of ALDH (D’Ambrosio et al., 2006; Hammen et al., 2002; Hurley et al., 
1999). Briefly, NAD(P)
+
 binding in the Rossmann fold of the enzyme activates the cata-
lytic cysteine (Cys302) nucleophile (Hammen et al., 2002). Cys302 then performs a nu-
cleophilic attack on the carbonyl carbon of the aldehyde. This forms a thiohemiacetal in-
termediate that facilitates hydride transfer to the cofactor. This results in the formation of 
a thioacylenzyme intermediate. Hydrolysis of the thioacylenzyme and release of the car-
boxylic acid product takes place via Glu268, which acts as a general base to activate the 
hydrolytic water after hydride transfer. The activated water performs a nucleophilic at-
tack on the carbonyl carbon displacing the carbon–sulfur bond and releasing the reduced 
cofactor NAD(P)H and product carboxylic acid. The order of product release is believed 
to be the product acid followed by reduced cofactor (Sohling et al., 1993) (Figure 2). 
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Figure 2. General reaction mechanism for aldehyde dehydrogenase. Figure shows 
detailed kinetic mechanism of conversion of aldehydes to carboxylic acid by ALDH3A1 
in the presence of NAD(P)
+
 and water. 
 
2. Important aldehyde dehydrogenase family members 
Structural, kinetic and knockout studies of several human aldehyde dehydrogenase 
isozymes have been performed over the years to understand their biological function. 
These studies have become important since lot of these enzymes show similarity in terms 
of structural packing, substrate preferences, catalytic residues and expression levels in 
cells despite being involved in completely different physiological processes or pathogen-
esis. Hence, a proper understanding of each of these isozymes is necessary for character-
izing their function with respect to different physiological processes. Some of the en-
zymes that have been extensively studied include ALDH1A1 (RALDH1), ALDH1A2 
10 
 
(RALDH2), ALDH1A3 (RALDH3), ALDH1B1, ALDH2 and ALDH3A1. All these iso-
zymes show broad tissue distribution, constitutive or inducible expression and oxidize a 
variety of aldehydes.  
ALDH1A1 is a tetrameric, cytosolic enzyme expressed in the adult epithelium of var-
ious organs including testis, brain, eye lens, liver, kidney, lung and retina (King et al., 
1997; Zhai et al., 2001). It is a highly conserved enzyme that can catalyze the oxidation 
of the retinol metabolite, retinaldehyde to retinoic acid (Zhao et al., 1996; Wang et al., 
1996). It has high affinity for the oxidation of both all–trans and 9–cis–retinal (Yoshida 
et al., 1992). Retinoic acid regulates gene expression by serving as a ligand for nuclear 
retinoic acid receptors and retinoid X receptors. It is important for normal growth, differ-
entiation, development and maintenance of adult epithelia in vertebrate animals (Ross et 
al., 2000). During embryogenesis, ALDHs have shown to exhibit differential expression 
patterns especially in retinoid dependent cells, indicating that retinoic acid signaling is 
essential for embryogenesis (Haselbeck et al., 1999; Niederreither et al., 2002; Marlier et 
al., 2004; Dickman et al., 1997; Duester et al., 2000). ALDH1A1 knockout mice 
(Aldh1a1
-/-
) are viable and have normal retina morphology. However, later during their 
life, they display reduced retinoic acid synthesis and increased retinal levels in serum af-
ter retinol treatment (Fan et al., 2003; Molotkov et al., 2003). Aldh1a1
-/-
 mice are protect-
ed against diet–induced obesity and insulin resistance, suggesting that retinal may tran-
scriptionally regulate the metabolic response to high–fat diets. Hence, ALDH1A1 may be 
a candidate for therapeutic targeting (Ziouzenkova et al., 2007). In cultured hepatic cells, 
suppression of ALDH1A1 gene reduced both omega oxidation of free fatty acids and the 
production of reactive oxygen species (Li et al., 2007). Retinoid X Receptor alpha 
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knockout (RXRα-/-) mice display decreased liver ALDH1A1 levels, suggesting that retin-
oic acid binding is an activating factor in ALDH1A1 gene expression (Gyamfi et al., 
2006). Retinoic acid is required for testicular development, and ALDH1A1 is absent in 
genital tissues of humans with androgens receptor–negative testicular feminization 
(Yoshida et al., 1993; Yoshida et al., 1998; Pereira et al., 1991).  
ALDH1A1 is also highly expressed in dopaminergic neurons that require retinoic ac-
id for their development and differentiation (Galter et al., 2003; Jacobs et al., 2007). In 
these neurons, ALDH1A1 expression is under the control of the transcription factor, 
Pitx3, which regulates the specification and maintenance of distinct populations of dopa-
minergic neurons through ALDH1A1 up–regulation (Chung et al., 2005). Decreased lev-
els of ALDH1A1 occur in dopaminergic neurons of the substantia nigra in Parkinson’s 
disease (PD) patients and in dopaminergic neurons of the ventral tegmental area in schiz-
ophrenic patients (Galter et al., 2003; Mandel et al., 2005). In the central nervous system, 
monoamine oxidase (MAO) metabolizes dopamine to its aldehyde form 3, 4–
dihydroxyphenylacetaldehyde (DOPAL). DOPAL may be neurotoxic, and its accumula-
tion may lead to cell death associated with neurological pathologies such as Parkinson’s 
disease. ALDH1A1 plays a critical role in maintaining low intraneuronal levels of DO-
PAL by catalyzing its metabolism to 3, 4–dihydroxyphenylacetic acid (DOPAC) (Galter 
et al., 2003). 
ALDH1A1 is involved in metabolism of the acetaldehyde, a metabolite of ethanol. 
Acetaldehyde is toxic at high concentrations in cells (Ueshima et al., 1993). Low activity 
of ALDH1A1 accounts for alcohol sensitivity in Caucasian populations (Ward et al., 
1994; Yoshida et al., 1989). Decreased levels of ALDH1A1 reported in RXRα-/- mice are 
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susceptible to alcoholic liver injury (Gyamfi et al., 2006). ALDH1A1 also plays a key 
role in the cellular defense against oxidative stress by oxidizing lipid peroxidation prod-
ucts–derived aldehydes. These include 4–HNE, hexanal, and malondialdehyde (MDA) 
(Manzer et al., 2003).  
ALDH1A1 also plays an important role in cancer. ALDH1A1 activity has been re-
ported to decrease the effectiveness of some oxazaphosphorine anticancer drugs, such as 
cyclophosphamide (CP) and ifosfamide, by detoxifying their major active aldehyde me-
tabolite, aldophosphamide (Sladek et al., 1999). Indeed, inhibition of ALDH1A1 activity 
leads to increased toxicity of the major metabolite of CP, 4–
hydroperoxycyclophosphamide (Moreb et al., 2007). Patients with low breast tumor 
ALDH1A1 levels have been reported to respond to cyclophosphamide–based treatment 
significantly more often than those with high levels, indicating that ALDH1A1 may be a 
predictor of the drug’s therapeutic effectiveness (Sladek et al., 2002). Various non–
cancerous cells, such as hematopoietic progenitor cells, express relatively high levels of 
ALDH1A1 and hence are relatively resistant to oxazaphosphorine–induced toxicity 
(Sladek et al., 1994). ALDH1A1 has also been shown to bind to certain anticancer drugs 
such as daunorubicin (Banfi et al., 1994) and flavopiridol (Schnier et al., 1999).  
Recent studies have shown that increased ALDH activity is a hallmark of cancer stem 
cells (CSC) that can be detected through the Aldefluor assay (Storms et al., 1999). The 
Aldefluor assay quantifies ALDH activity by measuring the conversion of BODIPY ami-
noacetaldehyde to the fluorescent reaction product BODIPY aminoacetate. Addition of 
the ALDH inhibitor diethylaminobenzaldehyde (DEAB) reduces fluorescence that con-
firms that ALDH positive cells are correctly identified. This assay was developed by suc-
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cessful isolation of viable hematopoietic stem cells from human umbilical cord blood and 
was reported to be specific for ALDH1A1 (Storms et al., 1999). However, while ALDH 
isoforms show substrate specificity, they also have cross–reactivity that makes it likely 
that the assay is detecting the ALDH activity of other ALDH isoforms as well. A recent 
ALDH1A1 knockout study showed that ALDH1A1 expression was not required for hem-
atopoietic and neural stem cell function (Levi et al., 2008). Despite not having 
ALDH1A1 expression, these stem cells did not show reduction in aldefluor activity, sug-
gesting that additional factors are responsible for aldefluor activity (Levi et al., 2008). 
Instead authors detected expression of ALDH2, ALDH3A1 and ALDH9A1 in the 
ALDH1A1–deficient hematopoietic cells that implies that one or more of these isoforms 
are responsible for the Aldefluor activity (Levi et al., 2008). In another study conducted 
in prostate cancer cell lines, high expression of ALDH7A1 was found with much lower 
expression of ALDH1A1 (van den Hoogen et al., 2010). These cells, however, showed 
very high Aldefluor activity suggesting that ALDH7A1 might be a contributor for Alde-
fluor activity as well (van den Hoogen et al., 2010). Another study with breast cancer pa-
tient tumor samples isolated for Aldefluor positive and Aldefluor negative tumor cells 
shows that at least for breast cancer stem cells, ALDH1A1 expression is not the primary 
determinant of Aldefluor activity (Marcato et al., 2011). Indeed, a proper correlation of 
ALDH1A3 and Aldefluor activity was seen in these cells. Expression and quantification 
of all 19 forms of ALDH in breast cancer cell lines revealed that ALDH1A3 expression 
correlated best with the ALDH activity. Only knockdown of ALDH1A3 reduced ALDH 
activity in all three Aldefluor positive breast cancer cells (Marcato et al., 2011). Howev-
er, it still leaves a possibility that other ALDH isoforms including ALDH1A1 have a po-
14 
 
tential to promote Aldefluor activity in breast cancer cells if expressed at sufficient levels. 
Based on all these studies, it becomes clear that ALDH isoforms responsible for Aldeflu-
or activity vary depending on cancer type and tissue of origin.  
ALDH1A2 is another cytosolic isozyme that plays an important role in retinoid syn-
thesis during embryonic development. Knockout studies have shown that it is the major 
retinoic acid–synthesizing enzyme during early embryogenesis (Haselbeck et al., 1999). 
ALDH1A2 knockout mice induced lethal defects in heart and forebrain development 
(Ribes et al., 2006). Transgenic mice lacking ALDH1A2 expression die at mid–gestation 
without undergoing axial rotation. They also show shortened anterioposterior axis and do 
not form limb buds. Their heart consists of single, medial, distal cavity and their fron-
tonasal region is truncated (Niederreither et al., 1999). A recent study has shown that 
ALDH1A2 is expressed in normal prostrate epithelia but is down–regulated in prostate 
cancer (Kim et al., 2005). Thus ALDH1A2 may function as a tumor suppressor in pros-
tate cancer (Kim et al., 2005). This also leaves a possibility of a role for retinoids in the 
prevention or treatment of prostate cancer.  
ALDH1A3 is a cytosolic homotetramer that is expressed at low levels in organs and 
tissues. Its expression in salivary gland, stomach and kidney are much higher than other 
tissues in body (Hsu et al., 1994). It is also differentially activated during early embryon-
ic head and forebrain development. Studies showed that ALDH1A3 knockout mice have 
reduced retinoic acid synthesis that cause malformations restricted to ocular and nasal 
regions are similar to that observed in Vitamin A–deficient mutants or retinoid receptor 
mutants (Dupe et al., 2003). ALDH1A3 knockout causes choanal atresia (nasal blockage 
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by soft tissue) that is responsible for the respiratory distress and resulting death of the 
mice (Dupe et al., 2003). 
ALDH1B1 is mitochondrial homotetramer that is known to be expressed in liver, tes-
tis, kidney, skeletal muscle and fetal tissues (Hsu et al., 1991). It exhibits ~72% sequence 
homology to ALDH2 and is insensitive to inhibition by disulfiram. 
ALDH2 is an important mitochondrial enzyme that is constitutively expressed in a 
variety of tissues including liver, kidney, heart, lung and brain (Goedde et al., 1990). It is 
the primary enzyme responsible for oxidation of acetaldehyde during ethanol metabolism 
(Klyosov et al., 1996). To date, several ALDH2 mutants have been reported, including 
the most widely studied ALDH2*2 allele (single base pair mutation G/ C A/ T) that 
results in an E487K or E504K mutation. Glu487, located in the bridging domain, main-
tains a stable scaffold and facilitates catalysis by linking together the cofactor–binding 
and catalytic domains through its interaction with Arg–264 and Arg–475 (Larson et al., 
2005; Larson et al., 2007). Since ALDH2 functions as a homotetramer, when ALDH2*2 
allele is dominant, heterotetrameric ALDH2 proteins containing even one ALDH2*2 
subunit are enzymatically inactive (Crabb et al., 1989). The ALDH2*2 allele is found in 
approximately 40% of individuals of Asian descent (Goedde et al., 1992). It causes alco-
hol induced toxicity in those who drink alcohol primarily due to acetaldehyde accumula-
tion (Wall et al., 1999; Peng et al., 2007). This is one of the reasons for lower alcoholism 
rate in Asian populations (Luczak et al., 2002). Studies have shown the association of 
ALDH2*2 with an increased risk for various cancers, including esophageal, stomach, co-
lon, lung, head, and neck cancers (Muto et al., 2000). Alcoholic ALDH2*2 individuals 
display increased levels of acetaldehyde–derived DNA adducts, indicating a potential 
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mechanism of DNA damage and cancer development (Matsuda et al., 2006). ALDH2*2 
has been associated with alcoholic liver disease and cirrhosis in Asian individuals, even 
with moderate alcohol intake (Enomoto et al., 1991). ALDH2*2 allele may also be a risk 
factor for increased DNA damage in workers exposed to polyvinyl chloride, a carcinogen 
that is metabolized to the ALDH2 substrate chloroactaldehyde, which produces DNA 
crosslinks and strand breaks (Wong et al., 1998; Spengler et al., 1988). 
In addition to acetaldehyde metabolism, ALDH2 is the principle enzyme responsible 
for the first step in the bioactivation of nitroglycerin, a long used treatment for angina and 
heart failure (Chen et al., 2002). The ALDH2*2 allele is associated with lack of nitro-
glycerin efficacy in Chinese patients (Li et al., 2006), increased myocardial damage fol-
lowing infarction in Korean patients (Jo et al., 2007) and hypertension in Japanese pa-
tients (Hui et al., 2007). Aldh2
-/-
 mice display increased alcohol toxicity correlating with 
increased brain and blood acetaldehyde levels (Isse et al., 2005; Isse et al., 2005) and in-
creased urinary 8–hydroxdeoxyyguanosine and DNA–acetaldehyde adducts after expo-
sure to acetaldehyde or oral ethanol administration (Ogawa et al., 2006, Ogawa et al., 
2007). The results were not seen in mice with normal ALDH2 expression.  
ALDH2 is reported to be associated with hepatotoxicity in alcoholics, late onset of 
Alzheimer’s and Parkinson’s disease. Hepatotoxicity in alcoholics occurs due to competi-
tion of lipid peroxidation product–derived aldehydes with acetaldehyde for ALDH2–
mediated metabolism. ALDH2 is involved in the metabolism of LPO–derived aldehydes, 
including 4–HNE and malondialdehyde (MDA) (Vasiliou et al., 2004). ALDH2 specifi-
cally seems to be responsible for 4–hydroxynonenal elimination in hepatic and Kupffer 
cells (Reichard et al., 2000; Luckey et al., 2001). ALDH2 activity is activated in the cere-
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bral cortex of Alzheimer’s disease patients, which may be a protective mechanism 
against high 4–HNE levels (Picklo et al., 2001). In vitro, ALDH2–deficient cells are 
highly vulnerable to 4–HNE induced apoptosis (Ohsawa et al., 2003). ALDH2*2 is asso-
ciated with elevated risk for the late onset of AD in Chinese population (Wang et al., 
2008). It is involved in metabolism of the neurotoxic aldehyde metabolite of dopamine, 
DOPAL; and hence deficiency of ALDH2 may contribute to the onset of Parkinson’s dis-
ease (Maring et al., 1985).  
ALDH3A1 is another cytosolic 55 KDa homodimer expressed in various tissues in-
cluding cornea, stomach, esophagus and lung. It is believed to be an important enzyme 
involved in cellular defense against oxidative stress (Estey et al., 2007). It catalyzes the 
oxidation of various LPO–derived aldehydes including α, β–hydroxyalkenals (Pappa et 
al., 2003). ALDH3A1 also functions as corneal crystallin and is highly expressed in cor-
neal epithelium, accounting for as much as 50% of the total water–soluble protein (Estey 
et al., 2007; Pappa et al., 2001). Aldh3a1
-/-
 mice show clear corneal tissue, but when ex-
posed to UV light, these mice show cataract formation and corneal opacification (Nees et 
al., 2002; Lassen et al., 2007). Aldh3a1
-/-
 mice show increased levels of 4–HNE and 
MDA–protein adducts (Lassen et al., 2007). Low expression of ALDH3A1 is associated 
with corneal disease (Pei et al., 2006) while overexpression in human corneal epithelial 
cells makes these cells less sensitive to UV light and UV associated cytotoxicity (Pappa 
et al., 2003). Enzymatic action of ALDH3A1 may also generate NADPH, which is criti-
cal for GSH maintenance and antioxidant retention (Kirsch et al., 2001). In vitro, 
ALDH3A1 prevents UV–induced protein inactivation and, in vivo, UV light inactivates 
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ALDH3A1 while other metabolic enzymes are unaffected, suggesting that ALDH3A1 
may function to absorb UV–light as part of a suicide response (Downes et al., 1993).  
ALDH3A1 also influences cell proliferation and the cell cycle. Cell lines expressing 
high levels of ALDH3A1 are more resistant to the anti–proliferative effects of lipid pe-
roxidation derived aldehydes and ALDH3A1 deficiency or ALDH3A1 inhibition reduces 
cellular growth rates through aldehyde accumulation (Canuto et al., 1999, Muzio et al., 
2003). In vitro, ALDH3A1 has been shown to prevent DNA damage and reduce apopto-
sis from various toxins including hydrogen peroxide and etoposide, indicating that 
ALDH3A1–mediated cell cycle delay and subsequent decreased cell growth is associated 
with resistance to DNA damage (Lassen et al., 2006). ALDH3A1 has also been identified 
as a potential diagnostic marker for non–small–cell lung cancer (Kim et al., 2007) and as 
a candidate gene in the pathogenesis of esophageal squamous cell carcinoma (Huang et 
al., 2000). Interestingly, while ALDH3A1 is expressed at low levels in normal liver, its 
expression in hepatoma cells increases in direct correlation with the growth rate of the 
tumor (Canuto et al., 1994). ALDH3A1 is induced in other neoplastic tissues and cell 
lines (Sreerama et al., 1997), and its expression is differentially affected by hormones 
such as progesterone and cortisone, suggesting a potential role in hormone dependent tu-
mors (Stephanou et al., 1999). ALDH3A1 expression is also induced by various xenobiot-
ics, including polycyclic hydrocarbon (PAHs) and 3–methylcholanthrene (Reisdorph et 
al., 2007). 
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3. ALDH3A1 and its importance in cancer chemoresistance 
ALDH3A1 was originally designated as the tumor ALDH, as it was found highly ex-
pressed in some human tumors such as hepatoma, lung adenocarcinoma, myeloma, breast 
cancer as well as in stem cell populations (Sreerama et al., 1993, Sreerama et al., 1997). 
ALDH3A1 is known to catalyze the metabolic inactivation of oxazaphosphorines such as 
cyclophosphamide and its analogs and contribute to drug resistance in various tumor 
types (Figure 3) (Manthey et al., 1990; Sreerama et al., 1993). Differential expression of 
ALDH3A1 may account for the variable clinical responses to cyclophosphamide treat-
ment in certain cancers (Sreerama et al., 1997; Sladek et al., 2002). In support of this hy-
pothesis, ALDH3A1 knockdown increases cellular sensitivity to cyclophosphamide and 
its metabolite, 4–hydroperoxycyclophosphamide (Moreb et al., 2007), and transfection of 
ALDH3A1 into normal human peripheral blood hematopoietic progenitor cells results in 
increased resistance to cyclophosphamide (Wang et al., 2001). ALDH3A1 can also be 
expressed in certain tumor cells by inducing these cells with catechol. MCF–7 cells in-
duced with 30 µM catechol for 5 days (MCF–7/ CAT) show much higher levels of cyto-
solic class–3 aldehyde dehydrogenase (ALDH3A1) than control cells (MCF–7). As a re-
sult of ALDH3A1 expression, MCF–7/ CAT cells are >35–fold more resistant to oxaza-
phosphorine treatment as compared to control (MCF–7) cells (Sreerama et al., 1995). 
Cellular levels of ALDH–3 activity were also increased when a number of other human 
tumor cell lines, e.g. breast adenocarcinoma MDA–MB–231, breast carcinoma T–47D 
and colon carcinoma HCT 116b, were cultured in the presence of catechol (Sreerama et 
al., 1995). The cultured human colon carcinoma cell line, Colon C has elevated cytosolic 
ALDH3A1 expression and shows intrinsic cellular resistance to mafosfamide (Ganaganur 
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et al., 1994). Colon C cells were found to be 10–fold less sensitive to mafosfamide than 
were two other cultured human colon carcinoma cell lines, RCA and HCT 116b, that do 
not express ALDH3A1 (Ganaganur et al., 1994). RCA and HCT 116b cell lysates had 
200–fold less aldehyde dehydrogenase activity (NADP+ dependent benzaldehyde oxida-
tion) as compared to colon C cells. Interestingly, the three cell lines were equally sensi-
tive to phosphoramide mustard, the final cross linking product of cyclophosphamide acti-
vation that cannot be detoxified by ALDH3A1. The relative insensitivity of Colon C can-
cer cells to mafosfamide was not seen in the presence of the competitive substrates ben-
zaldehyde, or 4–diethylaminobenzaldehyde, since these substrates compete with 
mafosfamide binding and its detoxication. Sensitivity of HCT 116b and RCA cells to 
both mafosfamide and phosphoramide mustard was unaffected when drug exposure was 
in the presence of the same substrates (Ganaganur et al., 1994). Similarly, another study 
performed with putative ALDH3 inhibitors (NPI–2)–[(4–chlorophenyl) sulfonyl–[2–
(methylpropan–2–yl) oxycarbonyl] amino] acetate and (API–2)–1–(4–chlorophenyl) sul-
fonyl–1–methoxy–3–propylurea sensitized MCF–7/ 0/ CAT cells to mafosfamide treat-
ment; the LC50 decreased from >2mM to 175 µM and 200 µM, respectively (Ganaganur 
et al., 1998). MCF–7 cells electroporated with ALDH3A1 were 16–fold less sensitive 
toward mafosfamide than control cells (Sreerama et al., 1995).  
Some antineoplastic agents induce apoptosis in cancer cells by producing oxidative 
stress through generation of lipid peroxidation products. ALDH3A1 can detoxify the 
products of lipid peroxidation and hence facilitate drug resistance. In fact, a recent study 
has shown that ALDH3A1 is one of the downstream targets of metadherin (MTDH), an 
important contributor toward multidrug chemoresistance (Hu et al., 2009). LM2 cells en-
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gineered to express an inducible shRNA against ALDH3A1 for conditional knockdown 
were more sensitive to chemotherapeutic agents such as paclitaxel, doxorubicin and 4–
hydroxycyclophosphamide when ALDH3A1 was knocked down. Also constitutive over-
expression of ALDH3A1 in LM2 cells was able to partially rescue the chemoresistance to 
paclitaxel, doxorubicin and 4–hydroxycyclophosphamide (Hu et al., 2009). These studies 
highlight the role of ALDH3A1 in a broad–spectrum of cancer chemoresistance and sup-
port the development of selective, potent small molecule inhibitors. 
 
4. Cyclophosphamide and its mechanism of cytotoxicity 
Cyclophosphamide and related oxazaphosphorines are clinically important 
antineoplastic and immunosuppressive agents. Even today, 52 years after their initial syn-
thesis, it is still widely used as a chemotherapeutic agent and in the mobilization and con-
ditioning regimens for blood and marrow transplantation. Reviewing the chemistry and 
pharmacology of cyclophosphamide is crucial for understanding its wide therapeutic ap-
plicability. Cyclophosphamide is, in fact, a prodrug activated by cytochrome P450 to 
produce an equilibrium mixture of aldophosphamide and its tautomeric isomers, cis and 
trans 4–hydroxycyclophosphamide (Figure 3). Aldophosphamide undergoes a non–
enzymatic β–elimination reaction to give the active antineoplastic agent phosphoramide 
mustard (Sladek et al., 2002). Phosphoramide mustard acts as an alkylating agent that 
cross links DNA and renders target cells nonviable (Figure 3) (Sladek et al., 2002). 
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Figure 3. Metabolic pathway for cyclophosphamide. Figure shows the metabolic acti-
vation of cyclophosphamide by P450 or spontaneous activation of mafosfamide to form 
4–hydroxycyclophosphamide that eventually from phosphoramide mustard. ALDH3A1 
acts on one of the intermediate aldophosphamide to form inactive carboxyphosphamide. 
 
5. Cytotoxic action of phosphoramide mustard 
The cytotoxic action of phosphoramide mustard is closely related to the reactivity 
of the 2–chloroethyl groups attached to the central nitrogen atom. Under physiological 
conditions, phosphoramide mustard undergoes an intramolecular cyclization through 
elimination of chloride forming a cyclic aziridinium cation. This highly unstable cation is 
readily attacked by several nucleophiles, including the N9 nitrogen in guanine residues in 
nucleic acids. This reaction releases the nitrogen of the alkylating agent and makes it 
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available to react with the second 2–chloroethyl group, facilitating the formation of a 
second covalent linkage with another nucleophile. By forming an interstrand DNA cross-
link the target cell is rendered non–viable (Figure 4) (Sladek et al., 2002). 
 
Figure 4. Phosphoramide mustard and its mechanism of DNA cross linking. Figure 
represents how phosphoramide mustard forms intrastrand and interstrand cross–links be-
tween guanine bases from DNA.  
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B. Hypothesis and approaches 
Hypothesis 
Since ALDH3A1 is involved in metabolism of aldophosphamide (activated form of cy-
clophosphamide), we hypothesized that inhibition of catalytic activity of ALDH3A1 us-
ing a small molecule inhibitor will increase cyclophosphamide chemosensitivity in cells 
that express ALDH3A1 as a mode of cyclophosphamide chemoresistance. 
 
Approaches 
The overall goal of this work is to identify and characterize selective inhibitors of 
ALDH3A1 that can enhance the sensitivity of chemotherapeutic agents such as cyclo-
phosphamide as well as tease out the contributions to aldophosphamide metabolism in 
tumor cells. Several approaches have been used to accomplish the objectives of research: 
(1) In vitro high throughput screen for inhibitor identification (2) Steady state competi-
tion assays for determining mode of inhibition (3) X–ray crystallographic studies of en-
zyme inhibitor complexes (4) Site directed mutagenesis for locating residues crucial for 
interaction (5) Structure Activity Relationship experiments to map out the basis of selec-
tivity and potency (6) Chemosensitivity experiments in cancer cells that do or do not ex-
press ALDH3A1. 
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II. Materials and Methods 
Materials 
Chemicals and reagents for the experiments were purchased from Bio–Rad Laborato-
ries (Hercules, CA), Corning Costar (Cambridge, MA), Fisher (Pittsburg, PA), GE 
Healthcare (Piscataway, NJ), Gibco BRL Technologies (Gaithersburg, MD), Hyclone 
(Logan, UT), Invitrogen (Carlsbad, CA), Sigma Aldrich (St. Louis, MO), Roche Applied 
Science (Indianapolis, IN), Santa Cruz Biotechnology Inc. (Santa Cruz., CA), Thermo 
Scientific (Rockford, IL). PEG3350 was purchased from Hampton Research (Laguna 
Niguel, CA). Compounds for high–throughput screening were purchased from Chem-
Bridge Corporation and ChemDiv Corporation. Lead compounds were purchased from 
Enamine Corporation (Kiev, Ukraine) and through the Indiana University Chemical Syn-
thesis Core.  
 
Methods 
A. Purification of ALDH3A1 
 The full–length cDNA for human ALDH3A1 was purchased from Open Biosys-
tems and subcloned into the pET–28a expression plasmid and used to transform E. coli 
BL21 (DE3). The resulting cells were grown in LB medium in the presence of kanamycin 
(50 μg/ mL final concentration) at 37°C until absorbance at 600 nm reached 0.6. At that 
point, isopropyl β–thiogalactopyranoside (IPTG; 0.1 mM final concentration) was added 
to induce the synthesis of ALDH3A1, and the cells were incubated for an additional 16 
hours at 16°C, and collected by centrifugation. The cell pellets were resuspended in Buff-
er A (20 mM sodium HEPES, 300 mM NaCl pH 7.8, 2 mM benzamidine, 1 mM beta–
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mercaptoethanol) and lysed by passage through a French Press operated at 13, 000 psi. 
The lysate was clarified by centrifugation at 100, 000xG for 45 minutes at 4°C in a 
Beckman Ti45 rotor. The lysate supernatant was loaded onto a nickel–NTA column, and 
the fractions were eluted using gradient elution of Buffer B (20 mM sodium HEPES, 300 
mM sodium chloride, 500 mM imidazole pH 7.8, 2 mM benzamidine, 1 mM betamercap-
toethanol). The eluted fractions from the nickel–NTA column were analyzed by SDS gel 
to confirm the presence of ALDH3A1 protein. Those fractions containing protein were 
pooled and dialyzed against two changes of Buffer C (10 mM sodium HEPES pH 7.8, 1 
mM benzamidine, 1 mM sodium EDTA, and 1 mM dithiothreitol) at 4°C. The dialyzed 
fractions were loaded onto a Q–sepharose column equilibrated in Buffer C and were elut-
ed using Buffer D (10 mM sodium HEPES, 250 mM NaCl, pH 7.8, 1 mM benzamidine, 1 
mM EDTA and 1 mM dithiothreitol). Fractions containing the ALDH3A1 protein were 
once again pooled and dialyzed against Buffer E (10 mM sodium HEPES pH 7.8, 1 mM 
dithiothreitol) at 4°C. The dialyzed protein was concentrated using a protein concentrator 
(Amicon Ultra–0.5 Centrifugal Filter Devices) operated with 30, 000 Dalton molecular 
weight cutoff membranes. The concentrated protein was filtered, and its concentration 
and specific activity were determined before flash freezing aliquots in liquid nitrogen and 
storing at −80°C. ALDH1A1 and ALDH2 protein was purified and kindly provided by 
Lanmin Zhai.  
 
B. Activity assays for ALDH1A1, ALDH2 and ALDH3A1 
The activity of ALDH3A1 was measured using two different methods–oxidation 
of benzaldehyde and hydrolysis of para–nitrophenylacetate. The dehydrogenase activity 
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was assayed spectrophotometrically on a Beckman DU–640 by monitoring the increase 
in absorbance at 340 nm due to NADPH formation (molar extinction coefficient of 6, 220 
M
−1
 cm
−1
) in a  solution containing 6.8 nM of ALDH3A1, 1 mM benzaldehyde and 1.5 
mM NADP 
+
  in 100 mM sodium phosphate buffer, pH 7.5 (Figure 5). The esterase activ-
ity was assayed spectrophotometrically by monitoring the formation of para–nitrophenol 
at 405 nm (molar extinction coefficient of 18, 000 M
−1
 cm
−1
) in a solution containing 180 
nM ALDH3A1, and 0.8 mM para–nitrophenylacetate in 25 mM sodium HEPES buffer, 
pH 7.0 (Figure 5).  
 
 
 
 
 
 
100 mM Na2HPO4 (pH 7.5), 1.5 mM NADP
+
, 6 nM ALDH3A1, 1 mM Benzaldehyde 
 
 
 
 
 
 
25 mM BES, pH 7.0, 180 nM ALDH3A1, 0.8 mM p–NPA 
 
Figure 5. Catalysis of benzaldehyde and para–nitrophenylacetate by ALDH3A1. 
Figure showing the reaction mechanisms of dehydrogenase and esterase assay catalyzed 
by ALDH3A1. The standard condition for a 15 minute linear reaction is also shown. 
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ALDH2 and ALDH1A1 based activity was assayed spectrophotometrically on a 
Beckman DU–640 by monitoring the increase in absorbance at 340 nm due to NADH 
formation (molar extinction coefficient of 6, 220 M
−1
 cm
−1
) in a  solution containing 100 
nM of ALDH1A1/ ALDH2, 1 mM propionaldehyde and 1.5 mM NAD 
+
  in 100 mM 
BES, pH 7.5. All assays were initiated by the addition of substrate, following a preincu-
bation with inhibitors for 2 minutes. 
 
C. High Throughput Screening (HTS) assay 
1) Reagent preparation and principle of assay 
 High–throughput screening was carried out using the esterase assay. This assay is 
more suitable for screening because the spectral properties of para–nitrophenol do not 
overlap with the absorbance and fluorescence characteristics of most compounds in the 
library. The substrate 4 mM para–nitrophenylacetate is prepared by adding 0.0725 grams 
of substrate powder in 6 mL of 100 % DMSO solvent. The substrate volume is then in-
creased to 100 mL by adding 94 mL of water. Enzyme is diluted to a concentration of 
0.045 mg/ mL using buffer 10 mM HEPES, pH 7.5, 10 µM DTT. Aldi–3 stock for the 
experiment was prepared such that final solution had 10 µM compound contained in 2% 
DMSO.  
 
2) Z’ Factor Measurement 
A standard statistical value known as the Z’ factor, which reflects the reliability of the 
screen, was calculated before initiating the high–throughput screen. A Z’ factor value be-
tween 0.5 and 1.0 is an indication of an excellent assay, and a value between 0 and 0.5 is 
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an indication of a poor assay (Zhang et al., 1999). To calculate the Z’ factor measure-
ment, positive and negative control reactions were carried out in 384 well plates. The 
control reaction included 800 µM para–nitrophenylacetate, 0.009 mg/ mL of ALDH3A1 
contained in 25 mM HEPES, pH 7.0 (2% DMSO) in a 50 µL reaction volume. The inhi-
bition reaction included all the above mentioned components as well as 10 µM of Aldi–3 
(Khanna et al., 2011). Aldi–3 is a covalent inhibitor of aldehyde dehydrogenase that 
forms adduct with the active site cysteine (Cys243) of ALDH3A1 and inhibits it activity 
(Khanna et al., 2011). The assay was carried out for 15 minutes and then the rates of the 
control and inhibition reactions (384 points for each set of reactions) were used to calcu-
late the Z’ factor using the following formula: 
Z’ factor    
        
       
 
Where δp= standard deviation of the control reaction, δn= standard deviation of the inhi-
bition reaction, µp= average of the points in the control reaction and µn=average of the 
points in the inhibition reaction (Zhang et al., 1999). 
 
3) HTS assay to identify potential inhibitors of ALDH3A1 
Library of diverse drug–like compounds that follow Lipinski’s rule (Lipinski et 
al., 2004) were screened at the Indiana University Chemical Genomics Core Facility. The 
chemical library was composed of 101, 000 compounds, among which 64, 000 were from 
ChemDiv Corp. and 37, 000 were from ChemBridge Corp. All the compounds were pre-
sent in 10 µL aliquots in 2% DMSO at 50 µM concentration in a 384 well plate format. 
The Genesis (Tecan) Workstation 150, TeMo with a 96–channel pipetting head was used 
to make all the reagent additions. Screening was done on 384 well clear bottom plates 
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using the esterase assay by monitoring the absorbance of para–nitrophenol at 405 nm 
wavelength in a 50 µL assay containing 180 nM ALDH3A1, 0.8 mM para–
nitrophenylacetate, 10 µM library compound, 2% DMSO and 25 mM sodium HEPES 
buffer, pH 7.5 (all final concentrations) on a Spectromax Plus 384 plate reader over a 10–
minute period. The reaction was initiated by the addition of substrate (para–
nitrophenylacetate). Every assay plate included one column each for the positive and 
negative control for the assay. The negative control lane contained the enzyme with no 
inhibitors but 2% DMSO whereas the positive lane contained 5 µM Aldi–3 incubated 
with ALDH3A1. DMSO (2%) had no effect on ALDH3A1 activity under this condition. 
The rates of reaction were used to determine percent inhibition, and the rate of reaction 
for ALDH3A1 protein without inhibitors was considered as the 100% control. Subse-
quent inhibition by compounds was considered relative to that of the control.  
% activity=  
                              
                                 
     
Compounds that showed more than 60% inhibition in the primary screen were 
taken for secondary screening to validate the inhibition. Compounds whose inhibition 
could be reproduced were further tested for their ability to inhibit the dehydrogenase, as-
sayed with the Beckman DU–640 UV–Vis spectrophotometer. Basic selectivity for the 
inhibitors was tested using purified recombinant ALDH1A1 and ALDH2 enzymes. 
ALDH1A1 and ALDH2 activities were assayed spectrophotometrically by monitoring 
the absorbance at 340 nm in a solution containing 1.5 mM NAD
+
, 200 µM propionalde-
hyde, 10 µM inhibitors, 0.16 µM of enzyme, in 25 mM sodium BES buffer, pH 7.5 
(Weiner et al., 1976; Parajuli et al., 2011; Perez Miller et al., 2003). Compounds that 
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strongly inhibited ALDH3A1 and only minimally inhibited ALDH1A1 and ALDH2 were 
selected for IC50 determination.  
IC50 values were further determined against propionaldehyde oxidation (for 
ALDH1A1 and ALDH2) or benzaldehyde oxidation (for ALDH3A1). This was per-
formed spectrophotometrically on a Beckman DU–640 by monitoring NAD(H) or 
NAD(P)H formation (molar extinction coefficient of 6220 M
-1
cm
-1
 at 340 nm) over time 
at various concentrations of inhibitors ranging from 50 nM to 250 µM following a 1 mi-
nute pre–incubation. All reactions were initiated by the addition of the aldehyde sub-
strate. The inhibition curves were fit to the Logistic four parameter IC50 equation using 
the sigma plot (v11, StatSys). All data represent the average of three independent sets of 
experiments with each set of experiments performed twice.  
 
D. Structural classification of compounds 
A series of compounds that independently emerged from the screen had similarity in their 
molecular structures in at least 50% of their atomic positions. These compounds were all 
classified under different categories based on these similarities. Some of the compounds, 
however, had no similarities with each other at all. IC50 values were determined for 
ALDH3A1, ALDH2 and ALDH1A1 based dehydrogenase assay for all these related ana-
logs. Specificity of these compounds was tested as well against ALDH1A1 and ALDH2. 
 
E. Steady–state kinetic characterization 
We characterized the mode of inhibition using steady–state kinetics through co-
variation of inhibitor and substrate concentrations. However, before doing that Km (con-
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centration required for half maximal velocity) values were determined for both benzalde-
hyde and NADP
+
. The steady state kinetic measurements were then performed in 100 
mM Na2HPO4 buffer, pH 7.5. The reaction mixture contained 10 nM ALDH3A1, varied 
NADP
+
 (50 µM–1 mM; fixed benzaldehyde, 1 mM) or varied benzaldehyde (50 µM–800 
µM; fixed NADP
+
, 1.5 mM) and varied inhibitor concentrations. In all cases including 
the control reactions lacking inhibitors, the final reaction mixture contained 2% (v/ v) 
DMSO. The reaction was initiated by addition of substrate, and the initial rate of for-
mation of product was determined on a Beckman DU–640. All data were fitted to select-
ed kinetic expressions for competitive, non–competitive, mixed–type non–competitive 
and uncompetitive inhibition. Appropriateness of the inhibition model was determined 
through analysis of goodness–of–fit and the residuals of those fits. Lineweaver–Burke 
plots were created using Sigma Plot (v11, StatSys) to visualize the inhibition patterns. All 
data represent the average of three independent experiments utilizing duplicate assays at 
each concentration point. 
 
F. Search for structurally related analogs 
 A structural search was performed using Pubchem (Kaiser et al., 2005) and 
Scifinder software in order to identify commercially available analogs with at least 90% 
structural similarity on their atomic positions with the lead compounds CB7 and CB29. 
Several compounds were purchased from ChemBridge Corp. and ENAMINE Ltd., Kiev, 
Ukraine and Indiana University Chemical Synthesis and Organic Drug Lead Develop-
ment Core. The purity of the compounds according to the vendor was >95%. Compounds 
were dissolved and diluted in 100% DMSO and stored at -20ºC. The analogs were tested 
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for their selectivity against ALDH1A1 and ALDH2 and ALDH3A1 at 100 µM concen-
trations. IC50 values were determined for the analogs with significant selectivity. The first 
class of compounds had N–[4–{(4–(methylsulfonyl)–2–nitrophenyl) 4amino} phenyl] 
acetamide group as a basic pharmacophore. Analogs related to this group were named as 
follows: A1– (ChemBridge Corp.– 5119656), A18– (ENAMINE– T5477155), A57– 
(ChemBridge Corp.– 6809058), B1– (ENAMINE– T56333437), B2– (ENAMINE– 
T5477154), B4– (ENAMINE–T5395179), B5– (ENAMINE–T5237743), B6– 
(ENAMINE–T05126153), B9– (ENAMINE– T5804455), B10– (ENAMINE– 
T5662523), B11– (ENAMINE– T5655673), B13– (ENAMINE– T6245968), B15– 
(ENAMINE– T6241917), B16– (ENAMINE– T6053724), B17– (ENAMINE– 
T6036772), B18– (ENAMINE– T6032083), B19– (ENAMINE– T6266966), B21– 
(ENAMINE– T6560452), B22– (ENAMINE– T6536700), IUSC–12415, IUSC–12416 
and IUSC–12417. The second class of compounds had 1–{(4–fluorophenyl) sulfonyl}–2–
methyl–1H–benzo[d]imidazole group as a basic pharmacophore. Analogs related to this 
group were named as follows:  
 
Compounds Vendors with ID numbers 
A3 (ChemBridge Corp.–5172826) 
A5 (ChemBridge Corp.–5172831) 
A6 (ChemBridge Corp.–5175600) 
A10 (ChemBridge Corp.–5215982) 
A13 (ChemBridge Corp.–5231103) 
A16 (ChemBridge Corp.–5243439) 
A20 (ChemBridge Corp.–5260321) 
A21 (ChemBridge Corp.–5264371) 
A22 (ChemBridge Corp.–5284379) 
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A24 (ChemBridge Corp.–5510049) 
A30 (ChemBridge Corp.–5607189) 
A38 (ChemBridge Corp.–5648440) 
A39 (ChemBridge Corp.–5651872) 
A40 (Vitas M. Laboratories.–STK354007) 
A47 (ChemBridge Corp.–6104618) 
A53 (ChemBridge Corp.–6382505) 
A62 (ChemBridge Corp.–7224032) 
A64 (ChemBridge Corp.–7289639) 
A67 (ChemBridge Corp.–7567094) 
A70 (ChemBridge Corp.–7928260) 
B27 (Vitas M. Laboratories.–STK454495) 
B36 (ChemDiv Corp. 6529–0359) 
B37 (ChemDiv Corp. K783–5471) 
CB7 (ChemBridge Corp.–5613645) 
 
 
G. Site directed mutagenesis 
 In order to characterize the binding pattern of CB7 to the catalytic site of 
ALDH3A1, two important mutations were made. Point mutations of ALDH3A1 were 
performed using QuickChange (Qiagen) mutagenesis. ALDH3A1 mutants were con-
structed using forward primer 5’–CTT CAA CCT CAC CAT CGC GCC CAT GGT 
GGG CGCC–3’ and complement for Q122A and forward primer 5’–CCT TCA ACC 
TCA CCA TCT GGC CCA TGG TGG GCG CCA TC–3’ and complement for Q122W 
mutant. These two mutant proteins were purified exactly the same way as was 
ALDH3A1. Mutants were frozen in 50mM NaCl. However, the yield was significantly 
decreased as compared to WT protein. Q122A was stored at 0.9 mg/ mL concentration 
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and Q122W was stored at 0.4 mg/ mL concentration at -80ºC. Kinetic experiments were 
performed exactly the same way as WT enzyme.  
 
H. Preparation and crystallization of ALDH3A1 with compounds 
ALDH3A1 crystals were grown in solution containing 0.2 M potassium acetate, 
20% PEG 3350 at a temperature of 25ºC. The enzyme concentration was 3–3.5 mg/ mL, 
in 10 mM HEPES buffer, pH 7.5. Various crystal morphologies form under these condi-
tions. CB29–ALDH3A1 complex crystal was obtained in P1 space group (triclinic crys-
tal), CB25–ALDH3A1 co–crystal was obtained in P212121 space group (orthorhombic 
crystal) and CB7–NAD+–ALDH3A1 co–crystal was obtained in P21 space group (mono-
clinic crystal). Crystal of different morphologies were obtained for each complexes be-
cause CB29–ALDH3A1 complex crystal was obtained by soaking experiment, CB25–
ALDH3A1 complex crystal was obtained by co–crystallization and CB7–ALDH3A1 was 
obtained in the presence of NAD
+
. The triclinic ALDH3A1 crystals were initially soaked 
with 2% DMSO for 24 hours followed by another 24 hour soak with 500 µM CB29 [2% 
(v/ v) DMSO final]. Initial soak with DMSO was performed because direct soaking with 
500 µM CB29 in 2% (v/ v) DMSO cracked the apo–crystals. Crystal for CB25–
ALDH3A1 was obtained using co–crystallization method by using 500 µM CB25 co–
crystallized with 4 mg/ mL of ALDH3A1 using the sitting drop method. These crystals 
were orthorhombic plates. The third crystal structure of CB7 bound to ALDH3A1 along 
with NAD
+
 were obtained using 1 mM NAD
+
, 1000 µM CB7 and 4 mg/ mL of 
ALDH3A1. The drop size was 8 µL with 1000 μLs of mother liquor. All these crystals 
were obtained using the sitting drop method. Crystals were directly frozen without using 
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any cryoprotectant. Datasets were collected at a wavelength of 0.9869 Å and at 100 K at 
the Advanced Photon Source using the GM/ CA–CAT beamline 23–ID located at Ar-
gonne National Laboratory. The diffraction data was indexed, integrated and scaled using 
the HKL3000 program (Minor et al., 2006). All refinements were performed using the 
program package REFMAC5 as implemented in the CCP4 program suite (Minor et al., 
2006) and model inspection and building was accomplished using COOT (Emsley et al., 
2004). All these structures were solved by performing molecular replacement using the 
apo–form of ALDH3A1 structure as the search model (RCSB code 3SZA). Molecular 
replacement was performed using MolRep program provided by CCP4 Interface soft-
ware. Initial maps showed clear electron density for the corresponding ligand bound on 
the active site of each monomer in the asymmetric unit. Atomic co–ordinates of bound 
ligands were included in later stages of refinement. Water molecules were added after the 
addition of ligands in order to obtain an unbiased map for ligands. Ligand maps were 
sketched in Sketcher (provided by CCP4). This structure was used to create library de-
scription file (cif file– defining the bond angle, bond lengths, etc.) and a coordinate file 
for the ligand, which were later used for refinement. 
 
I. Cell culture 
Lung adenocarcinoma (A549), SF767 and CCD13–Lu cell lines were provided by 
Dr. Hua Lu, Dr. X. Charlie Dong, Dr. Karen Pollok and Dr. Melissa L. Fishel respective-
ly. A549, HEK–293 and CCD13Lu cells were cultured in 1X DMEM (Cellgro, Medi-
atech Inc, Manassa, VA) supplemented with 10% fetal bovine serum (FBS) (Gibco, Invi-
trogen Company, Grand Island, NY), 100 units/ mL of penicillin and 10 µg/ mL of strep-
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tomycin. SF767 cell lines were cultured in 1X IMDM (Gibco, Invitrogen Company, 
Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen 
Company, Grand Island, NY), 100 Units/ mL penicillin and 10 µg/ mL streptomycin. The 
multiple myeloma (MM) cells U266, H929 and RPMI–8226 were kindly provided by Dr. 
Attaya Suvannasankha. These cell lines were cultured in RPMI 1640 media (Gibco, Invi-
trogen Company, Grand Island, NY) and supplemented with 10% heat–inactivated fetal 
bovine serum (FBS) (Gibco, Invitrogen Company, Grand Island, NY), 100 units/ mL 
penicillin and 10 µg/ mL streptomycin. Cell viability as assessed by tryphan blue exclu-
sion was consistently >95%. Cells were passaged after every 80–90% confluence. 
 
J. Cell lysate activities in the presence and absence of ALDH3A1 inhibitors 
Cells (A549, HEK–293, SF767 and CCD13Lu) were washed with ice cold PBS to re-
move residual media. 400 µL of RIPA buffer (Cell signaling technologies) containing 1 
mM PMSF (Sigma Aldrich) was added to each 10 cm dish. Plates were incubated on ice 
for 5 minutes. Plates were scraped and lysates were collected. Lysates were centrifuged 
for 10 minutes at 16, 000xG in a micro–centrifuge at 4°C. Protein concentrations of the 
supernatant were measured using the Bradford reagent (Biorad Laboratories). 50 µg of 
cell lysate was used in the activity assay. We calculated the activity of cell lysates using 
1.5 mM NADP
+
 (co–factor) and 1 mM benzaldehyde (substrate) and reaction buffer (100 
mM Na2HPO4, pH 7.5). Reaction was blanked with cell lysate containing 1 mM benzal-
dehyde and reaction buffer (100 mM Na2HPO4, pH 7.5) without NADP
+
. This was per-
formed to blank any ALDH associated activity that could be contributed by NAD
+
 that is 
present in cell lysates. ALDH3A1 activity in cell lysates were measured in 100 mM 
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Na2HPO4 buffer at pH 7.5, with 1.5 mM NADP
+
 and 1 mM benzaldehyde. Activity assay 
was also performed with 1 µg of recombinant ALDH3A1 in the presence and absence of 
ALDH3A1 inhibitors. This was performed to normalize the amount of ALDH3A1 pre-
sent in cell lysates from cancer cells. All assays contained 1% (v/ v) DMSO. Lysates 
were treated with these compounds for 1 minute before the substrate was added and 
measurements were taken. 
 
K. Western blot analysis 
Cells (A549, HEK–293, SF767 and CCD13Lu) cells were washed with ice cold 
PBS to remove the residual media. 400 µL of RIPA buffer (Cell signaling technologies) 
containing 1 mM PMSF (Sigma Aldrich) was added to each 10 cm dish. Plates were in-
cubated on ice for 5 minutes, scraped and lysates were collected. Lysates were subjected 
to sonication for 30 seconds and centrifuged for 10 minutes at 16, 000xG in a micro–
centrifuge at 4°C. Protein concentrations were measured using the Bradford reagent (Bio-
rad Laboratories). A549, HEK–293, SF767 and CCD13Lu cell lysates were resolved by 
10% SDS–PAGE. Protein was transferred to 0.2 µm nitrocellulose membrane (Schleicher 
& Schuell, Keene, NH) and subsequently blocked with 5% (w/ v) nonfat dry milk dis-
solved in TBS–T (20 mM Tris/ HCl (pH 7.9), 150 mM NaCl, and 0.05% Tween 20) solu-
tion for 1 hour at 25 ºC. This was followed by an overnight incubation at 4º C with pri-
mary antibody specific for ALDH3A1 (Santa Cruz Biotechnology, sc–67310) at a dilu-
tion of 1: 5000 in 5% (w/ v) nonfat dry milk. ALDH1A1 was detected using primary an-
tibody (ab–23375, Abcam) at a dilution of 1: 1000 in 5% (w/ v) nonfat dry milk over-
night at 4º C. Blots were washed with TBS–T three times, 15 minutes each and were sub-
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sequently incubated with secondary antibody (sc–2054 for ALDH3A1 and ab6721 for 
ALDH1A1) at a dilution of 1: 5000 for 1 hour at 4º C. GAPDH was taken as a loading 
control. GAPDH was blocked with 1.25% of filtered milk solution. GAPDH was detected 
using primary antibody (ab9484 diluted in 1.25% filtered milk in a ratio of 1: 5, 000) fol-
lowed by secondary antibody (ab6728 diluted in 1.25% filtered milk in a ratio of 1: 
5000). Proteins bound to antibodies were visualized using HRP chemiluminescence im-
munoblot detection solution prepared in lab. HRP chemiluminescence solution is made 
up of mixture of solution 1 and solution 2 in a ratio of 1: 1. Solution 1 contains (50 µL of 
2500 mM Luminol, 22 µL of 90 mM Coumaric acid, 0.5 mL of 1M Tris pH 8.5, and 4.46 
mL of deionized water. Similarly, solution 2 contains 3 µL of hydrogen peroxide dis-
solved in 0.5 mL of 1M Tris pH 8.5, and 4.5 mL of deionized water. The mixed HRP so-
lution was incubated for a minute before adding it to the nitrocellulose blot incubated 
with primary and secondary antibody. All experiments were performed in triplicates.  
 
L. MTT assay to evaluate cell proliferation 
The MTT assay was used to measure the extent of mafosfamide chemosensitivity. 
Mafosfamide was used for this study primarily because it is an analog of cyclophospha-
mide that does not require cytochrome P450 for its activation, which is ideal for cell 
based studies (Blaney et al., 2005). The MTT assay was optimized for each cell line such 
that the number of cells utilized for the experimental treatments corresponded to the line-
ar range of the assay measurements. The results of these standardization measurements 
indicated that 5000 cells/ well was optimal for A549 and CCD13Lu and 10, 000 cells/ 
well was optimal for the HEK–293 and SF767 cell line. An optimization trial was per-
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formed for lung adenocarcinoma (A549), glioblastoma (SF767), human embryonic kid-
ney (HEK–293) and lung fibroblast (CCD13Lu) cell line to find the approximate ED50 
value of mafosfamide (Niomech– IIT GmbH, Bielefeld, Germany); 125 μM for A549 
cells, 150 μM for SF767 cells, 80 μM for HEK–293 and 40 μM for CCD13Lu cell line 
(Figure 28). Following optimization, A549 (5, 000 cells/ well), HEK–293 (10, 000 cells/ 
well), SF767 (10, 000 cells/ well) and CCD13Lu (5000 cells/ well) cells were seeded in 
96 well plates. After 29 hours, A549 and SF767 cells were treated with ALDH3A1 inhib-
itors in the absence or in the presence of 125 µM mafosfamide. HEK–293 and CCD13Lu 
cells were treated with ALDH3A1 inhibitors in the absence or in the presence of 80 µM 
and 40 µM mafosfamide respectively. The MTT assay was carried out following 19 
hours of incubation with the inhibitors and/ or mafosfamide. To visualize cellular prolif-
eration, 0.01 mL of MTT (Millipore CT01–5, 50 mg/ mL in PBS) was added to each 
well, and the cells were incubated for 2–3 hours at 37º C to allow for the reduction of 
MTT. Isopropanol with 0.04 N HCl (100 µL each) was added and mixed thoroughly for 
color development. After an additional hour of incubation, the absorbance was measured 
at 570 nm using a reference wavelength at 630 nm. For the calculation, absorbances 
measured at 570 nm were corrected through background subtraction using the absorbance 
at 630 nm. The relative percentage of cell proliferation was calculated in comparison to 
DMSO (0.25%) treated controls. The time points for treatment were chosen based on 
similar experiments performed earlier (Khanna et al., 2011). 
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III. Results 
A. Protein purification 
His–tagged ALDH3A1 was cloned onto pET28a vector by our lab member Dr. Su-
lochanadevi Baskaran. ALDH3A1 protein was purified using Ni–NTA affinity followed 
by Q–sepharose column. Upon IPTG induction (50 μg/ mL), we saw expression of 
ALDH3A1 (Figure 6A). Protein was loaded to a Ni–NTA column and was eluted using 
an imidazole gradient as shown below. These fractions were run on a 10% SDS–PAGE 
gel to analyze the fractions that had ALDH3A1 (Figure 6B). Fractions that showed max-
imal expression of ALDH3A1 with minimal contamination of other proteins (fractions 
12–18) were pooled together and dialyzed against Buffer C (10 mM sodium HEPES pH 
7.8, 1 mM benzamidine, 1 mM sodium EDTA, and 1 mM dithiothreitol) at 4°C.
 
Figure 6. SDS–PAGE for Ni–column fractions. (A) ALDH3A1 expression after induc-
tion with IPTG. (B) Fractions of ALDH3A1 ran on SDS PAGE gel after running it 
through the nickel column. 
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The dialyzed fractions were loaded onto a Q–sepharose column equilibrated in Buffer C 
and then eluted using gradient of Buffer D (10 mM sodium HEPES, 250 mM NaCl, pH 
7.8, 1 mM benzamidine, 1 mM EDTA and 1 mM dithiothreitol). Several fractions were 
collected from the Q column and again run on 10% SDS–PAGE gel to analyze the frac-
tions that had ALDH3A1 (Figure 7). Proteins eluted from the Q–column showed almost 
no contamination of any other protein except for ALDH3A1. Pure protein (fraction 15–
23) were pooled together, concentrated up to 4 mg/ mL and stored at -80ºC. Standard ac-
tivity assay conditions were optimized for ALDH3A1 activity. 
 
Figure 7. SDS–PAGE for Q–column fractions. ALDH3A1 fractions collected after 
running it through Q column fractions were pure with optimal specific activity (32 U/ 
mg). 
 
Assay condition for determining the activity of ALDH3A1 
 
Final conc. Volume 
100mM Na2HPO4, pH 7.5 100 mM 920 μL 
75 mM NADP
+
 1.5 mM 20 μL 
25 mM Benzaldehyde 2.5 mM 40 μL 
ALDH3A1 15 nM 20 μL 
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B. Z’ score calculation 
For high throughput screening, we used an assay system based on the inherent es-
terase activity of ALDH3A1. The esterase assay was selected for the primary screening 
assay because the absorbance of para–nitrophenol at 405 nm has minimal spectral overlap 
with the absorbance characteristics of the majority of compounds in the chemical library. 
In addition, the catalytic requirements for ester hydrolysis overlap with those required for 
propionaldehyde oxidation. Several optimization trials were performed before the screen. 
An assay condition containing 800 µM para–nitrophenylacetate, 0.009 mg/ mL of en-
zyme in 25 mM BES, pH 7.5 with 2 μM DTT was optimal for screening. 10 µM Aldi–3 
was added to the solution as a positive control. DTT was essential for the reaction since it 
is a reducing agent and keeps active site Cys302 in a reduced condition. Reactions that 
had no DTT showed ~40–50% less activity than the ones with DTT. Under this condi-
tion, the reaction was linear for 30 minutes and <10% of substrate was used. Using this 
assay condition, a Z’ experiment was conducted using 384 plate systems. Z’ is a measure 
that tells us how good a screen is. A score of more than 0.5 is equivalent to a separation 
of 12 standard deviations between µp and µn. Our Z’ score was 0.56 under these condi-
tions (Figure 8). 
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Figure 8. Z’ score calculation. Experiment for optimization of Z’ score before conduct-
ing high throughput screen. Enzyme substrate activity in the presence and absence of in-
hibitor Aldi–3 (covalent inhibitor of ALDH3A1) was calculated which did not show 
overlap up to 12 standard deviations.  
 
C. High throughput screen results 
I performed a primary screen of 101, 000 compounds available from two com-
mercial libraries (ChemDiv and ChemBridge). We had 64, 000 compounds available 
from ChemDiv library and 37, 000 compounds available from ChemBridge library. For 
our initial screen, we considered a compound as a hit if it showed an inhibition greater 
than 60% as compared to the control. Screening was performed in 384 well plates that 
had 16 rows and 24 columns. The first 22 columns in 384 well plates had 10 micromolar 
concentration of compound stock solution which was tested for inhibition of ALDH3A1 
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activity. An example of one of the 384 screening well plate screened is shown below 
(Figure 9).  
 
 
Figure 9. Screening result from one of the 384 well plates screened. X axis shows the 
corresponding column number in 384 well plates and Y axis shows the activity. Brown 
dot at F7 position shows a hit. Column 24 shows positive control for inhibition by Aldi3. 
 
In the first round of screening, 436 compounds were identified as potential inhibi-
tors. These compounds were cherry–picked from master plates and rescreened. Only 71 
compounds reproduced the inhibitory potency on our second round of assay. Rescreening 
of these compounds using benzaldehyde oxidation as the assay yielded 55 inhibitors that 
inhibited ALDH3A1 in both assays. All of the active compounds had molecular masses 
ranging between 300 and 600 Da; some sharing the same core structures. The independ-
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ent identiﬁcation of compounds with similar core structure provides conﬁdence that our 
screen has identiﬁed genuine ALDH3A1 inhibitors. These 55 compounds were classiﬁed 
into 11 different categories based on their structures, though some compounds were 
unique and lacked structural homologs in the initial inhibitor list. We determined IC50 
values for both the benzaldehyde oxidation and ester hydrolysis reactions for the best in-
hibitor prototype within each class of inhibitor. To assess the potential selectivity of these 
inhibitor compounds, we tested their ability to inhibit aldehyde oxidation of both 
ALDH1A1 and ALDH2. Steps for screening are summarized by Figure 10. 
 
S. No. Steps for screening Compounds 
1 In–vitro kinetic screen using esterase assay 101, 000 
2 Compounds with >60% inhibition 436 
3 Secondary screen by cherry–picking the initial hits 71 
4 Validation of inhibitors using dehydrogenase assay 55 
5 Structural classification of compounds 55  
6 Testing specificity against ALDH1A1 and ALDH2 55  
7 IC50 determination 3 
8 Selective inhibitors 2 
 
Figure 10. Various steps for high throughput screen. Different steps of high through-
put screening for identification and validation of selective inhibitors of ALDH3A1. 
 
Out of the two screens we looked at, we were not able to get isozyme selective inhibitor 
for ALDH3A1 from the ChemDiv library (64, 000 compounds). Therefore, we screened 
ChemBridge library (37, 000 compounds) to look for isozyme selective inhibitors. Over-
all, a variety of structures were obtained from our screen (Figure 11 and Figure 12). 
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 Figure 11. Structure of inhibitors that emerged from ChemDiv screen. Lot of the 
compounds that emerged as inhibitors from the screen showed structural similarity with 
each other. 
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Figure 11 (Continued). Structure of inhibitors that emerged from ChemDiv screen. 
Lot of the compounds that emerged as inhibitors from the screen showed structural simi-
larity with each other. 
49 
 
 
Figure 12. Structure of inhibitors that emerged from ChemBridge screen. Chem-
Bridge screen, despite having less number of compounds (37,000) than ChemDiv screen 
(64,000), provided us more hits and gave us two selective ALDH3A1 inhibitors CB7 and 
CB29 shown above.  
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Figure 12 (Continued). Structure of inhibitors that emerged from ChemBridge 
screen. A family of compounds having indole–2,3–dione group emerged as ALDH inhib-
itors, which showed varying degree of ALDH1A1 and ALDH3A1 inhibition based on 
minor substitutions at various positions. 
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Figure 12 (Continued). Structure of inhibitors that emerged from ChemBridge 
screen. Class of inhibitors with nitro subgroup inhibited ALDH3A1 but this class was not 
pursued since these compounds were not greatly potent. 
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Figure 12 (Continued). Structure of inhibitors that emerged from ChemBridge 
screen. These inhibitors were not pursued since they had weak potency and no specific 
selectivity pattern. 
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Two inhibitors (CB7 and CB29) from the ChemBridge collection showed high 
ALDH3A1 inhibition but no inhibition to ALDH1A1 and ALDH2 activity. Another 
compound CB25 showed greater inhibition to ALDH3A1 but had minor inhibition of 
ALDH1A1 activity at 10 μM concentration. Chart showing selectivity and potency of 
CB7, CB25 and CB29 is shown below in Figure 13. 
 
 
 
 
 
 Isozymes  CB7 (IC
50
) CB25 (IC
50
) CB29 (IC
50
) 
ALDH1A1 > 250 µM  20.0 µM  > 250 µM  
ALDH2 > 250 µM   > 250 µM   > 250 µM  
ALDH3A1 0.20 µM 1.80 µM 16.0 µM 
 
Figure 13. Three hit compounds CB7, CB25 and CB29 with their IC50 values. CB7, 
CB29 and CB25 are three hit compounds that emerged from the screen. CB7 and CB29 
are selective inhibitors for ALDH3A1 whereas CB25 inhibits ALDH1A1 and ALDH3A1 
but still exhibits ~10 fold higher selectivity to ALDH3A1. 
   CB25    CB7    CB29 
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D. Steady state kinetic characterization  
We characterized the mode of inhibition using steady–state kinetics through co–
variation of inhibitor and substrate concentrations. The steady–state kinetic measure-
ments were performed in 100 mM Na2HPO4 buffer, pH 7.5. Initial studies showed that 
NADP
+
 had a Km value of 260 μM whereas benzaldehyde had a Km value of 200 µM 
(Figure 14). Steady state competition experiments showed a competitive mode of inhibi-
tion for CB7 with respect to benzaldehyde with a Ki of 0.082 μM and non–competitive 
mode against NADP
+
 with a Ki of 0.11 μM (Figure 15). CB29 showed a competitive 
mode of inhibition with respect to both benzaldehyde and NADP
+
 with Ki values of 4.7 
μM and 3.9 μM respectively (Figure 16). CB25 showed a non–competitive mode of inhi-
bition with respect to both benzaldehyde and NADP
+
 with Ki values of 0.70 and 1.4 μM, 
respectively (Figure 17).  
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Figure 14. Km for NADP
+
 and benzaldehyde for ALDH3A1 activity. (A) Determina-
tion of Km for NADP
+
 for ALDH3A1. (B) Determination of Km for benzaldehyde. 
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(A) 
 
(B) 
 
Figure 15. Competition experiments of CB7 with benzaldehyde and NADP
+
. Compe-
tition experiment showing the mode of inhibition of CB7 with respect to (A) benzalde-
hyde and (B) NADP
+
. 
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(A) 
 
 
 
(B) 
 
Figure 16. Competition experiments of CB29 with benzaldehyde and NADP
+
. Com-
petition experiment showing the mode of inhibition of CB29 with respect to (A) benzal-
dehyde (B) NADP
+
. 
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(A) 
 
 
 
 
 
 
 
 
 
(B) 
 
Figure 17. Competition experiments of CB25 with benzaldehyde and NADP
+
. Com-
petition experiment showing the mode of inhibition of CB25 with respect to (A) NADP
+
 
(B) benzaldehyde. 
Ki = 1.4 μM 
59 
 
E. Structure Activity Relationship 
1. SAR by CB29 class of compounds 
We purchased 64 different compounds that showed at least 90% structural similarity 
in their atomic positions with CB29 and tested their selectivity for ALDH1A1, ALDH2 
and ALDH3A1 (Table 3A and 3B). Our results showed that only those CB29 derivatives 
with smaller subgroups, such as methyl or methylamine, at the R1 position were inhibito-
ry toward ALDH3A1 (Table 3A). Substitution of the R1 position with larger substituent, 
such as diethylamine or morpholine, eliminated inhibitory potency for ALDH3A1, but 
showed weak activation of ALDH1A1 activity [Table 3A, compare CB29 (IC50 = 16 μM) 
with B6 (NI) and B2 (IC50 = 26 μM) with B5 (NI) and B18 (NI)]. Since larger substitu-
tions were deleterious to potency, we examined whether substitution of the CH3 with CF3 
improved potency. Replacement of the methyl group with a tifluoromethyl group (CF3) at 
the R1 position generated an equally potent compound [Table 3A, compare CB29 (IC50 = 
16 μM) with 12415 (IC50 = 17 μM)]. We concluded that a methyl substituent was optimal 
at the R1 position. Next, we examined analog with a methyl sulfonyl group at R3 posi-
tion. Our SAR result showed that this substitution leads to both lower solubility (by more 
than 5–fold) and lower potency of compound [Table 3A, compare CB29 (IC50 = 16 μM) 
with 12416 (IC50 = 40 μM)]. In addition, this compound was less selective and inhibited 
both ALDH1A1 and ALDH3A1. Based on these results, we believe that the nitro group is 
advantageous for solubility and selectivity. Since CB29 had a substituted aniline group at 
the R2 position (Table 3B), we explored a number of different substituted anilines to test 
their contribution to the potency and selectivity of CB29. Our results showed that an ani-
line at the R2 position was required for inhibition of ALDH3A1 [Table 3B, compare A1 
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(NI), A57 (NI) with CB29 (IC50 = 16 μM), B1 (IC50 = 27 μM) and B4 (IC50 = 30 μM)]. 
Even the substitution of an ether linkage greatly reduced potency [Table 3B, compare 
CB29 (IC50 = 16 μM) with 12417 (IC50 = 100 μM)]. We evaluated a series of anilines at 
the R2 position with substitutions at the ortho, meta and para positions. Compounds with 
substituents at the ortho position (R4/R8) lost all activity toward ALDH3A1 [Table 3A, 
B17 (NI)]. Compounds with substitutions at the meta positions (R5/R7) showed similar 
potencies to CB29 [Table 3A, B15 (IC50 = 10 μM) and B21 (IC50 = 26 μM)]. Finally, we 
examined substitutions at the para (R6) position. Since our parent compound CB29 had 
an acetamide at this position, we looked for analogs with an ester instead of amide link-
age at the corresponding position (A18 and B11). This substitution yielded compounds 
with similar potencies [A18 (IC50 = 31 μM), B11 (IC50 = 24 μM)], which rules out a pos-
sibility of hydrogen bond formation by this nitrogen to the enzyme. We next looked larg-
er amide substitutions at the R6 position. Here a surprising pattern was seen, when the 
acetamide was substituted with isobutyramide (B13) or isopentanamide (B16), these two 
compounds were inhibitory towards both ALDH1A1 and ALDH3A1 (Table 3A). In addi-
tion, analogs with larger amides at the R6 position and larger substitutions at the R1 posi-
tion (B22) showed greater potency toward ALDH1A1 than toward ALDH3A1 (Table 
3A). In contrast, as mentioned above when the acetamide group was held constant and 
the larger morpholine was introduced at the R1 position (B6), the compound lost all in-
hibitory potency toward either ALDH1A1or ALDH3A1.Compounds having aniline at the 
R2 position with its meta and para position substituted with electronegative subgroups 
seemed to activate ALDH1A1 activity at 100 µM concentration (B21, B15, B2, B18, 
B11) by about 30%–50%.  
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Table 3. (A) SAR for CB29 analogs. SAR study for analogs having aniline at R3 posi-
tion but with ortho, meta and para substitutions at various positions (R4, R5, R6, R7 and 
R8). Also included are compounds with substitutions at R1 and R3 positions. Shaded in 
yellow are the residues of ALDH3A1 that are in close proximity with of CB29. 
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Table 3. (B) SAR for CB29 analogs. SAR showing the effect of first set of analogs that 
had substitutions other than aniline at R3 position (such as halogen, glycine and ethers). 
Values in parentheses are S.D. for three independent assays. NI stands for no inhibition at 
100 µM inhibitor concentration. WA represents (30–50) % activation shown by 100 µM 
compound to respective enzymes.  
 
  
 
 
 
 
63 
 
2. SAR by CB7 class of compounds 
We evaluated 118 different structurally related analogs of CB7 with at least 95% 
structural similarity for their inhibitory potency toward ALDH3A1 and selectivity versus 
ALDH1A1 and ALDH2 using the dehydrogenase assay. Substitutions were made at sev-
eral different positions. Representative compounds with their selectivity and potency pat-
tern in respective enzymes are shown in Table 4. We initially looked at the contribution 
of the methyl group at R1 position to see if any other substitutions in this region would 
make this compound more potent. Our SAR study showed that methyl substitution at R1 
position is optimal [compare A20 (IC50 0.3 μM) with A21 (IC50 1.5 μM) and A10 (IC50 
0.7 μM) with A3 (IC50 50 μM)]. However, aromatic or bigger substitutions were not tol-
erated [compare A6 (IC50 >100 μM) and A13 (IC50 >100 μM) with A20 (IC50 0.3 μM), 
A21 (IC50 1.5 μM), B36 (IC50 1.2 μM) and B37 (IC50 1 μM)]. Next, compounds modified 
in the R2 and R3 position were tested for their selectivity and potency. Our study showed 
that compounds having even a methyl substitution at R2 or R3 position showed no inhibi-
tion on ALDH3A1 activity (A38 and A47). One interesting feature of CB7 is the pres-
ence of fluorine atom at R6 position. We looked at analogs with different charges and 
sizes at the R6 position. Analogs with hydrogen, methyl, isobutyl, acetamide substitution 
at this position do not inhibit ALDH3A1 whereas fluorine or chlorine substitution was 
able to inhibit ALDH3A1 [compare A5 (IC50 >50 μM), A3(IC50 ~50 μM), A16 (IC50 
>100 μM)  and A67 (IC50 >100 μM) with A21 (IC50 >1.5 μM) and A24 (IC50 >2.1 μM)]. 
Since chlorine and fluorine are two strong electron withdrawing atoms, we believe that 
these two halogens enhance the hydrophobic interactions with the surrounding residues 
whereas an acetamide is electron donating and has the opposite effect [compare A20 
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(IC50 0.3 μM) with A22 (IC50 >100 μM)]. It could also be possible due to the steric effect 
since halogens are smaller subgroups whereas an acetamide is a bigger subgroup. Next, 
we looked at compounds with substitution at either the R4 or R8 position. Compounds 
with methoxy or halogen substitution at these two positions were not inhibitory to 
ALDH3A1 activity [compare A30 (IC50 >100 μM) with A20 (IC50 0.3 μM), A39 (IC50 
>100 μM) with A24 (IC50 2.1 μM) and A40 (IC50 >100 μM) with CB7 (IC50 0.2 μM)]. 
Even methyl substitutions at these two positions were not tolerated. Substitutions at either 
R5 or R7 were not greatly deleterious, but still showed some drop in their inhibitory po-
tency [compare A53 (IC50 0.7 μM) and A64 (IC50 0.9 μM) with A20 (IC50 0.3 μM) and 
A70 (IC50 0.9 μM) with CB7 (IC50 0.2 μM)]. Since all the analogs we tested had higher 
IC50 values than the CB7, we concluded that the commercially available analogs were not 
able to improve the potency of CB7. 
 
 
 
 
 
 
 
 
 
 
 
65 
 
Table 4. SAR for CB7 analogs. Values in parentheses represent standard error. NI 
stands for no inhibition and NI(A) stands for no inhibition but very weak activation 
(~20% at 100 μM). Residues of ALDH3A1 that are in close contact with CB7 are shown 
in yellow boxes.
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F. Crystal structures of inhibitors with ALDH3A1 
1. Crystal structure of ALDH3A1 with CB29 
In order to understand target specificity and provide a structural context for the kinet-
ic results, we determined the crystal structure of CB29 bound to ALDH3A1. CB29 was 
chosen because it had very high solubility in water, had reasonable potency (Ki = 4 µM) 
and showed good selectivity amongst its analogs. Since our analogs shared > 90% struc-
tural similarity to CB29, it also serves as a good starting point upon which to build the 
SAR on this series. Triclinic crystals were obtained that had unit cell dimensions of a = 
89.1 Å, b = 95.4 Å, c = 117.2 Å and diffracted up to 2.5 Å resolution. Four dimers are 
present in one asymmetric unit. Figure 18(A) shows one of the four independent dimers. 
The presence of CB29 within the active site of ALDH3A1 was confirmed through exam-
ination of the original figure–of–merit, σA–weighted, electron density maps (Figure 18B). 
The active site of all eight subunits of ALDH3A1 were fully occupied by CB29 (Figure 
18B). Detailed refinement statistics are provided in Table 5. In the Ramachandran plot, 
97% of all residues are in the most favored regions. There are four residues Cys243, 
Val244, Glu61 and Asn114 that contribute hydrogen bonding interactions with CB29 
(Figure 19). The two sulfonyl oxygens and the amino group linking the two benzene 
rings mediate these hydrogen bonds whereas the terminal benzene and acetamide moie-
ties contribute mostly hydrophobic and van der Waals interactions (Figure 19). One of 
the sulfonyl oxygens forms a hydrogen bond with the peptide nitrogen of Val244. The 
second sulfonyl oxygen is positioned similar to the oxyanion formed during catalysis and 
lies in proximity to the peptide nitrogen of Cys243 and the side chain amide nitrogen of 
Asn114. The nitrogen linking the two substituted benzene rings in CB29 donates a hy-
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drogen bond to the peptide carbonyl oxygen of Glu61. The remainder of the interactions 
between CB29 and the active site are hydrophobic and van der Waals contacts. The me-
thyl associated with the sulfonyl group forms a hydrophobic interaction with Phe401 and 
the nitro–benzene ring forms hydrophobic pi–stacking interactions with Tyr115. The side 
chains of Ile394 and Thr242 also contribute hydrophobic interactions with the nitro–
benzene ring. The second aromatic ring forms hydrophobic interactions with Tyr65 and 
Thr395 on one side, while the opposing face interacts with the Cβ and Cγ side chain at-
oms of Glu61 and the side chain of Met237. The terminal acetamide group is within van 
der Waals contact distance to Tyr65, Trp233, Thr395, Val 392 and Arg441 (Figure 19).  
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(A) 
 
 
Figure 18. (A) CB29 binding in ALDH3A1 pocket. A cartoon representation of one of 
the four independent dimers present in one asymmetric unit of ALDH3A1–CB29 com-
plex crystal structure. The individual subunits are colored orange and magenta. CB29 is 
shown using van der Waals spheres. 
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(B) 
 
 
Figure 18. (B) Electron density of CB29 bound to active site of ALDH3A1. The elec-
tron density maps displayed are the original figure of merit (σ–A weighted) Fo-Fc map 
contoured at 2.5 standard deviations (blue) and the original figure–of–merit weighted 
2Fo-Fc map contoured at 1 standard deviation (green) superimposed on the final refined 
model of CB29 bound in the enzyme active site. 
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Figure 19. Two dimensional map showing CB29 binding in ALDH3A1 pocket. Two 
dimensional representation of the important contacts between CB29 and residues within 
the active site of ALDH3A1. Pink dotted lines represent potential hydrogen bonding in-
teractions. The distance shown is the average of the distances observed in the eight subu-
nits of the asymmetric unit. Hydrophobic contacts are represented by purple arcs radiat-
ing towards the ligand. Regions that contribute hydrogen bonds are shaded green and 
those that contribute hydrophobic contacts are shaded red. 
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Table 5. Refinement statistics for CB29 bound to ALDH3A1. 
    ALDH3A1 (CB29 soak) 
Data collection 
 Space group P1 
Cell dimensions a = 89.1 Å, b = 95.4 Å, and c = 117.2 Å 
 
α = 112.4 °, β = 91.7 °, and γ = 91.0 ° 
Resolution (Å) 50–2.50 (2.54–2.5) 
Rmerge 0.067 (0.25) 
I/ σI 10.4 (3.1) 
Completeness 93.6 % (72.5%) 
Redundancy  2.2 (2.0) 
  Refinement 
 Resolution (Å) 50.0–2.50  
No. of reflections 109, 547 
Rwork/ Rfree 0.23/ 0.25 
  No. of atoms 
 Protein 28003 
Ligand/ Ion 192 
Water 218 
  B–factor (overall) 25.2 
  RMSD 
 Bond angles (°) 1.15 ° 
Bond lengths (Å) 0.008 Å 
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2. Crystal structure of ALDH3A1 with CB7 
The structure of ALDH3A1 with CB7 proved more difficult to obtain and required 
the presence of the cofactor NAD
+
 in order to obtain the complex. CB7 was chosen 
among all of these compounds because it was the most potent compound (Ki = 0.1 µM), 
exhibited very good solubility, and shared > 95% structural similarity to the other ana-
logs. Monoclinic crystals were obtained that belonged to space group P21 with unit cell 
dimensions of a = 95.2, b = 90.9, c = 117.9 and diffracted up to 1.9 Å resolution. Struc-
ture was determined by performing molecular replacement using the apo–form of 
ALDH3A1 structure as the search model (RCSB code 3SZA). Molecular replacement 
was performed using MolRep program provided by CCP4 Interface software. The pres-
ence of CB7 within the active site of ALDH3A1 was confirmed through examination of 
the original figure–of–merit, σA–weighted, electron density maps (Figure. 20). There are 
four subunits in one asymmetric unit arranged as two independent dimers. The active site 
is fully occupied by CB7 in two out of four subunits (Figure 20). The third and fourth 
subunit showed partial occupancy of CB7 in its catalytic site. Our structure also showed 
the presence of NAD
+
 inside the Rossmann pocket of all four subunits with full occupan-
cy (Figure 21A and 21B). Detailed refinement statistics are provided in Table 6. In the 
Ramachandran plot, 97.3 % of all residues are in the most favored regions. Interestingly, 
no hydrogen bonding interactions were observed between CB7 and ALDH3A1. Howev-
er, we observed numerous hydrophobic and van der Waals interactions between CB7 and 
ALDH3A1 (Figure 22). The benzene ring from benzimidazole forms hydrophobic con-
tact with Phe401, Tyr115, Leu119 and Cys243. The imidazole ring forms a strong hydro-
philic interaction with His 413 and Ile 394. The methyl group associated with imidazole 
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ring forms hydrophobic interaction with Tyr65 and Ile394. One of the sulfonyl oxygen 
forms van der Waals interactions with Tyr65, Glu62 and Asn118. The other sulfonyl ox-
ygen forms van der Waals interactions with Tyr115, Glu62 and Asn118. Benzene ring 
attached to fluorine form hydrophobic interactions with two tyrosine residues, Tyr65 and 
Tyr115 as well as with Thr395 and Glu61. The sulfonyl and attached fluorobenzene sub-
group lie symmetrically between Tyr115 and Tyr65, creating almost an equivalent hy-
drophobic interaction between two Tyrosine residues (Tyr65 and Tyr115). Hydrophobic 
contacts are also seen between fluorine and Ile391, Trp233 and Met237.  
In addition to CB7 binding, in our crystal structure we also see the presence of the co-
factor NAD
+
. NAD
+
 binds to ALDH3A1 through numerous hydrogen bonding interac-
tions. The amide nitrogen from the nicotinamide group forms a hydrogen bond with car-
bonyl oxygen from Leu210. The two hydroxyl groups from the nicotinamide ribose ring 
form two hydrogen bonding interactions with the two carboxyl oxygens of Glu333. Four 
oxygens from the two phosphates form four hydrogen bonds with Thr112, Trp113, 
His289 and Ser188, respectively. The two hydroxyl groups from the adenosine ribose 
ring form two more hydrogen bonds with carboxyl oxygens of Glu140. All of these hy-
drogen bonding interactions tightly bind NAD
+ 
in its Rossmann fold. In addition, several 
hydrophobic interactions are also present. A detailed two dimensional map for NAD
+ 
binding is shown in Figure 23. 
We compared interaction between NAD
+
 and ALDH3A1 with interaction pattern be-
tween NAD
+
 and ALDH2 (Perez–Miller et al., 2003). The NAD+ conformation in CB7 
bound ALDH3A1 structure exhibits a hydride transfer conformation in terms of binding 
partners and the types of interactions it forms with ALDH3A1. In ALDH2 structure, in 
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hydride transfer conformation (PDB code 1o00), amide nitrogen from nicotinamide 
group forms a hydrogen bond with Leu269. In ALDH3A1, we see hydrogen bond be-
tween amide nitrogen and Leu210. In ALDH2, we see two hydroxyl groups from the nic-
otinamide ribose ring forming two hydrogen bonding interactions with the two carboxyl 
oxygens of Glu399. In our structure, we see two similar hydrogen bonds between hy-
droxyl groups from the nicotinamide ribose ring and Glu333. Hydrogen bonds shown by 
two phosphate groups in ALDH2 are however not identical in ALDH3A1 structure. In 
ALDH2 structure, four oxygens from the two phosphates form hydrogen bonds with a 
Magnesium ion, Ser246 and Trp168. In ALDH3A1, we see interaction of four oxygens 
with Ser188, Trp113, Thr112 and His289 but not magnesium ion. In ALDH2, the two 
hydroxyl groups from the adenosine ribose ring form three hydrogen bonds with Ile166, 
Lys192 and Glu195. In ALDH3A1, these hydroxyl groups form hydrogen bond with ter-
minal carboxylic oxygens from Glu140. The adenine ring is not bonded to any residue 
but water in both ALDH2 and ALDH3A1. Overall, we see a lot of structural similarity in 
terms of binding both in NAD
+–ALDH2 as well as NAD+–ALDH3A1 structure in their 
hydride transfer conformation.  
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Figure 20. Density map showing CB7 bound to ALDH3A1. The electron density maps 
displayed are the original figure of merit (σ–A weighted) Fo-Fc map contoured at 2.5 
standard deviations (green) and the original figure–of–merit weighted 2Fo-Fc map con-
toured at 1 standard deviation (blue) superimposed on the final refined model of CB7 
bound in the enzyme active site. Residues that contribute to hydrophobic interactions 
within a distance of 3.4–4.0 Å are represented as sticks. 
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(A) 
 
 
Figure 21. (A) Map showing NAD
+
 binding to ALDH3A1 in the presence of CB7. 
Surface representation of the catalytic and NAD(P)
+
 binding site of ALDH3A1. NAD
+
 is 
bound on one pocket followed by binding of CB7 into the catalytic pocket. Bound lig-
ands are represented as sticks. 
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(B) 
 
 
Figure 21. (B) Electron density of NAD
+
 bound to ALDH3A1. The electron density 
maps displayed are the original figure of merit (σ–A weighted) Fo-Fc map contoured at 
2.5 standard deviations (green) and the original figure–of–merit weighted 2Fo-Fc map 
contoured at 1 standard deviation (blue) superimposed on the final refined model of 
NAD
+
 bound. Residues involved in catalysis; Cys243 and E209 and shown in sticks. 
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Figure 22. Two dimensional map showing CB7 contact with ALDH3A1. Hydropho-
bic interactions are shown by black arcs and van der Waals interactions are shown by 
blue arcs. 
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Figure 23. Two dimensional map showing NAD
+
 binding with ALDH3A1. Two di-
mensional map highlighting the hydrogen bonding interactions between NAD
+
 and resi-
dues of ALDH3A1 present in its Rossmann fold. Blue dotted lines represent the hydrogen 
bonding interactions with a distance of 2.4–3.2Å. 
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Table 6. Refinement statistics for CB7 bound to ALDH3A1. 
 
 Data collection ALDH3A1 (CB7 + NAD
+
 co–crystal) 
Space group P21 
Cell dimensions a = 95.2 Å, b = 90.9 Å, and c = 117.9 Å 
 
α = 90 °, β = 112.4 °, and γ = 90.0 ° 
Resolution (Å) 50–1.95 (1.98–1.95) 
Rmerge 0.072 (0.34) 
I/ σI 10.9 (4.5) 
Completeness 96.3 % (92.6%) 
Redundancy  2.8 (2.8) 
  Refinement 
 Resolution (Å) 108.96–1.94  
No. of reflections 125, 475 
Rwork/ Rfree 0.21/ 0.25 
No. of atoms 
      Protein 14073 
     Ligand/ Ion 267 
     Water 979 
B–factor (overall) 32.1 
RMSD Bond angles (°) 1.07 ° 
RMSD Bond lengths (Å) 0.05  
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3. Crystal structure of ALDH3A1 with CB25 
The chemical name of CB25 is 1–{[4–(1, 3–benzodioxol–5–ylmethyl) piperazin–1–
yl] methyl}–1H–indole–2, 3–dione. Orthorhombic crystals were obtained that belonged 
to space group P212121 with unit cell dimensions of a = 61.3, b = 86.4, c = 170.2 and dif-
fracted up to 2.3 Å resolution. Each asymmetric unit contained a dimer. Structure was 
determined by performing molecular replacement using the apo–form of ALDH3A1 
structure as the search model (RCSB code 3SZA). Molecular replacement was performed 
using MolRep program provided by CCP4 Interface software. In our electron density 
map, we see the presence of indole–2, 3–dione and piperazine group (Figure 24A). The 
group involved in forming the most crucial interaction is indole–2, 3–dione. The 3–keto 
group of the indole–2, 3–dione ring bound within the substrate binding site and forming 
an adduct with the active site nucleophile (Cys243 in ALDH3A1). The distance between 
Cys243 and the carbonyl–carbon, as well as the out–of–plane displacement of the car-
bonyl oxygen, is consistent with the formation of adduct between these two reactive 
groups. That this covalent bond is reversible is supported by the fact that addition of di-
thiothreitol to the reaction solution after preincubation restores the enzymatic activity. 
There is sufficient electron density to model the indole–2, 3–dione and the N–piperazine 
moiety, but insufficient electron density is present to model the terminal benzyl–dioxol 
moiety. Modeling of the benzyl–dioxol moiety onto the crystallographically observed 
partial structure, suggests that the benzyl–dioxol lies at the interface between the exit of 
the substrate binding site and bulk solvent. Two dimensional map showing interactions of 
CB25 with the ALDH3A1 active site residues is shown in Figure 24B. Detailed refine-
ment statistics are provided in Table 7. A detailed SAR study needs to be done to proper-
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ly analyze and understand how this compound can be made selective for ALDH3A1 
since it also inhibits ALDH1A1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
(A) 
 
 
Figure 24. (A) Density map showing the binding of CB25 with ALDH3A1. The elec-
tron density maps displayed are the original figure of merit (σ–A weighted) Fo-Fc map 
contoured at 2.5 standard deviations (green) and the original figure–of–merit weighted 
2Fo-Fc map contoured at 1 standard deviation (blue) superimposed on the final refined 
model of CB25 bound in the enzyme active site.  
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(B) 
 
 
Figure 24. (B) Two dimensional map showing CB25 binding with ALDH3A1. Two 
dimensional map highlighting interaction of CB25 with active site residues of 
ALDH3A1. CB25 forms a covalent adduct with Cys243 of ALDH3A1. In addition, we 
also see some hydrogen bonding interactions. Dotted lines represent the hydrogen bond-
ing interactions within a distance of 2.4–3.2 Å and dotted arcs indicate the residues in-
volved in hydrophobic interaction that lie within a distance of 3.4–4.0 Å from CB25. 
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Table 7. Refinement statistics for CB25 bound to ALDH3A1. 
 Data collection ALDH3A1 (CB25 co–crystal) 
Space group P212121 
Cell dimensions a = 61.3 Å, b = 86.4 Å, and c = 170.61 Å 
 
α = 90 °, β = 90 °, and γ = 90.0 ° 
Resolution (Å) 50.0–2.30 (2.34–2.30) 
Rmerge 6.0 (14.6) 
I/ σI 16.3 (6.7) 
Completeness 96.0 % (88.0 %) 
No. of reflections 39, 454 
Redundancy  3.4 (2.7) 
  Refinement 
 Resolution (Å) 48.0–2.30 
Rwork/ Rfree 17.5/ 22.2 
No. of atoms 
      Protein 6913 
     Ligand/ Ion 12 
     Water 649 
B–factor (overall) 18.47 
B–factor (protein) 18.40 
B–factor (ligand/ ion) 27.40/ 36.93 
B–factor (water) 21.03 
RMSD Bond angles (°) 1.143° 
RMSD Bond lengths (Å) 0.006 
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G. Expression and Activity of ALDH3A1 and ALDH1A1 in Cancer Cell Lines 
We examined various cancer cell lines to determine the level of ALDH1A1 and 
ALDH3A1 expression since these two enzymes are known to metabolically inactivate 
cyclophosphamide and its derivatives. As previously reported (Moreb et al., 2007), we 
found A549 cells express both ALDH1A1 and ALDH3A1 (Figure 25A, 25B). In our 
Western blot experiment, we saw the bands for recombinant ALDH3A1 slightly higher 
than that of ALDH3A1 from cell lysates. This is because our recombinant protein has a 
Histidine tag that gives it a slightly higher molecular weight. We quantified the relative 
expression levels of each isoenzyme through reference to purified recombinantly ex-
pressed enzymes. Based on these Western blots, A549 cells expresses ALDH1A1 at 
about 1% of total lysate protein and ALDH3A1 at about 2% of total lysate (Figure 26A 
and 26b). SF767 cells also demonstrated robust ALDH3A1 expression, but lacked detect-
able expression of ALDH1A1 (Figure 25A, 25B). HEK–293 and CCD13Lu cells had no 
detectable expression of ALDH1A1 or ALDH3A1 (Figure 25A and 25B).  
To confirm that protein expression correlates with ALDH activity, we performed ac-
tivity assays. While benzaldehyde is a substrate for either enzyme, ALDH1A1 will not 
use NADP
+
 as a cofactor, therefore the ability to oxidize benzaldehyde in this assay is 
primarily due to ALDH3A1 (Figure 27). A549 cell lysates had an activity of 282 nmol/ 
min/ mg. Based on the specific activity of recombinantly ALDH3A1 purified in our lab 
(32 μmol/ min/ mg), the activity assay confirmed the immunoblot and demonstrated that 
ALDH3A1 is active and present at ~2% of total lysate protein. Similarly, in SF767 cells, 
western blot analysis and enzyme assays show that ALDH3A1 is expressed at 1% of total 
cellular protein (Figure 26C). HEK–293 and CCD13Lu cells had no detectable 
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ALDH1A1 or ALDH3A1 activity as shown in western blot and enzyme activity assays 
(Figure 25A and 25B).  
The ability of CB29 to inhibit ALDH3A1 activity in cancer cell lysates was also ex-
amined using this same activity assay. As shown in Figure 27A, when CB29 is added to 
the A549 and SF767 cell lysates, the ALDH3A1 activity is diminished significantly: 
(~95% in A549; ~90% in SF767, right panel). The activity of the recombinant ALDH3A1 
also decreased significantly with 50 µM CB29 (~98%, Figure 27A, left panel). Cell lysate 
activity from SF767 and A549 were also decreased with CB7 and its analogs A10, A20, 
A21, A64, A70, B27 and B37 (Figure 27B). These data suggest that ALDH3A1 possess-
es robust activity in tumor cell extracts, and that CB29 and CB7 specifically target the 
activity of ALDH3A1 in the context of tumor whole cell lysates. These cell lines provide 
a convenient system to investigate the potentiation of mafosfamide by ALDH3A1 inhibi-
tion as A549 cells express both ALDH3A1 and ALDH1A1, SF767 cells express predom-
inantly ALDH3A1, and CCD13Lu or HEK–293 cells do not express detectable levels of 
several ALDH isoforms. 
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(A) 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. (A)  ALDH expression in A549, SF767, HEK293 and CCD13Lu cells. Ly-
sates from various cancer cell lines (A549, SF767, HEK–293 and CCD13Lu) were exam-
ined for ALDH3A1 expression. Purified recombinant His–tagged ALDH3A1 protein is 
taken as positive control and GAPDH serves as a loading control. Purified recombinant 
ALDH3A1 has a slightly higher band because it is His–tagged and travels slowly on 
SDS–PAGE gel. 
89 
 
(B) 
 
 
 
 
Figure 25. (B) Expression of ALDH1A1 in tumorigenic and non–tumorigenic cells. 
Lysates from various cancer cell lines (A549, SF767, HEK–293 and CCD13Lu) were ex-
amined for ALDH1A1 expression. Purified recombinant ALDH1A1 protein is taken as 
positive control and GAPDH serves as a loading control.  
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Figure 25. (C) Cross reactivity of ALDH1A1 antibody. Figure shows the cross reactiv-
ity of ALDH1A1 antibody, Abcam (ab–23375) with other ALDH subtypes. Human 
ALDH1 isoforms (ALDH1A1, ALDH1A2, ALDH1A3, and ALDH1B1) and ALDH2 
were purified in the lab and were provided by Lanmin Zhai. Each lane was loaded with 
between 50 and 70 ng of the purified recombinant human ALDH1A1, ALDH1A2, 
ALDH1A3, ALDH1B1 and ALDH2 isoenzymes respectively and were detected using 
ALDH1A1 antibody.  
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(A) 
 
 
 
Figure 26. Quantitation of ALDH1A1 and ALDH3A1 in A549 and SF767 cells. (A) 
Quantitation of ALDH1A1 expression in A549 cell line. Serial dilutions of A549 cell 
lysates (0.5 µg–22.5 µg) were compared against serial dilutions of recombinantly purified 
ALDH1A1 (5 ng–250 ng). Purified recombinant ALDH1A1 protein served as positive 
control and GAPDH served as a loading control. 
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(B) 
 
 
Figure 26. (B) Quantitation of ALDH3A1 expression in A549 cell line. Serial dilutions 
of A549 cell lysates (0.5 µg–22.5 µg) were compared against serial dilutions of recombi-
nantly purified ALDH1A1 (5 ng–50 ng). Purified recombinant His–tagged ALDH3A1 
protein served as positive control and GAPDH served as a loading control. 
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(C) 
 
 
Figure 26. (C) Quantitation of ALDH3A1 expression in SF767 cell line. Serial dilu-
tions of SF767 cell lysates (1 µg–10 µg) were compared against serial dilutions of re-
combinantly purified ALDH3A1 (50 ng–300 ng). Purified recombinant His–tagged 
ALDH3A1 protein served as positive control and GAPDH served as a loading control. 
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(A)
 
(B) 
 
Figure 27. ALDH3A1 inhibition in cancer cell lysates by ALDH3A1 inhibitors. 
A549, SF767, HEK–293 and CCD13Lu cell lysate activity were tested in the presence of 
1.5 mM NADP
+
 and 1 mM benzaldehyde and in the presence and absence of (A) 50 μM 
CB29 and (B) 10 μM CB7 and its analogs. The p values were calculated using the Stu-
dent’s t test comparing activity in the absence and presence of inhibitor (CB29) (*, p < 
0.001, n=3). 
95 
 
H. Sensitization of tumor cells to mafosfamide through inhibition of ALDH3A1  
ALDH3A1 has been shown to directly influence cellular sensitivity to the effects 
of cyclophosphamide treatment. We want to test the ability of our inhibitors to increase 
the sensitivity of tumor cells to cyclophosphamide and its derivatives as a means to widen 
the therapeutic window for this anti–neoplastic agent (Boesch et al., 1996; Sreerama et 
al., 1995). Toward this end, we evaluated the ability of CB7 and CB29 and selected ana-
logs to increase the sensitivity of lung adenocarcinoma (A549) and glioblastoma (SF767) 
cells toward mafosfamide. These compounds were chosen because they were selective to 
ALDH3A1 activity and showed no inhibition to ALDH1A1 activity or ALDH2 in vitro. 
Also these compounds had high solubility and could easily form a homogenous 100 µM 
solution in the presence of 0.25% DMSO and demonstrated the lowest general cytotoxici-
ty at concentrations as high as 100 µM. The ED50 values for mafosfamide on A549 and 
SF767 cells were 125 µM and 150 µM, respectively, while CCD13Lu and HEK–293 
cells were more sensitive to mafosfamide having an ED50 values of 40 µM and 80 µM, 
respectively (Figure 28).  
 
1. Treatment with CB29 analogs 
Treatment with mafosfamide decreased cell proliferation in all cell lines (Figure 
29A and 29B, DMSO control vs. mafosfamide, 100 % vs. 59 ± 14% (A549), p < 0.001, 
100% vs. 68 ± 4% (SF767), p<0.001). Treatment with ALDH3A1 inhibitors B1, B2, B4, 
B9, B11, B15, A18 and CB29 had little effect on cell proliferation (Figure 29A and 29B, 
grey bars) as single agents. At doses that inhibited ALDH3A1 in cell lysates (50 µM), we 
did not observe cytotoxicity in either A549 or SF767 cells except for analog B21 
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(p<0.005). We tested doses as high as 100 µM and did not see significant cytotoxicity in 
the absence of mafosfamide (data not shown). Co–treatment of cells with compounds B1, 
B2, B4, B9, B11, B15, as well as CB29 decreased cell proliferation relative to 
mafosfamide alone (Figure 29A and 29B). Similar experiments were performed with 
CCD13Lu and HEK293 cells (devoid of ALDH3A1 expression). Treatment with 
mafosfamide in the presence of ALDH3A1 inhibitors did not significantly enhance 
mafosfamide sensitivity in HEK–293 and CCD13Lu cells (Figure 29C and 29D). Since 
SF767 cells do not express ALDH1A1, we performed a dose–dependent study for sensi-
tization toward mafosfamide in these cells. We used the parent compound, CB29 as well 
as analogs B4 and B9 based on the degree of mafosfamide–induced enhancement we ob-
served in Panel A and B. We observed a dose–dependent decrease in cell proliferation 
(Figure 29E) as the concentration of compounds B4, B9 and CB29 increased.  
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Figure 28. Determination of mafosfamide ED50 values in various cell lines. 5000 
A549 and CCD13Lu cells and 10, 000 SF767 and HEK–293 cells treated with increasing 
concentration of mafosfamide. Figure shows logarithmic plot for approximate ED50 val-
ues of mafosfamide on various cell lines (A549, SF767, HEK293 and CCD13Lu respec-
tively). 
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Figure 29. Chemosensitivity experiments in cancer cells with CB29 analogs. Cells 
were simultaneously treated with mafosfamide (MF) in combination with ALDH3A1 in-
hibitors (50 µM). (A) A549 and (B) SF767 cells treated with mafosfamide (125 µM) for 
19 hours. (C) CCD13Lu cells treated with 40 µM mafosfamide for 19 hours. (D) HEK–
293 cells treated with 80 µM mafosfamide for 19 hours. Cell proliferation was deter-
mined using the MTT assay. The DMSO concentration was limited to 0.25% (v/ v). The 
p values were calculated by comparing the cellular proliferation of mafosfamide treated 
cells to that of mafosfamide in combination with ALDH3A1 inhibitor treated cells (*, p ≤ 
0.001, n = 10–15) or DMSO treated cells to that of compound treated cells (**, p ≤ 0.005, 
n = 10–15). Grey bars represent compound treatment alone and black bars represent 
compound and mafosfamide treatment. Each bar represents the mean value ± SE. (E) 
SF767 cells treated with increasing concentrations of B4, B9, and CB29 and either the 
presence or absence of 125 µM mafosfamide (n= 10–15). 
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2. Treatment with CB7 analogs 
Mafosfamide chemosensitivity experiments were also conducted with CB7 and its 
analogs A10, A20, A21, A64, A70, B37 and B27. All of these compounds were very se-
lective for ALDH3A1 activity and showed no inhibition to ALDH1A1 and ALDH2. 
These compounds also had high solubility and could easily form a homogenous 100 µM 
solution in the presence of 0.25% DMSO and demonstrated the lowest general cytotoxici-
ty at concentrations as high as 50 µM. Mafosfamide treatment decreased cell proliferation 
in all cell lines (Figure 30A and 30B, DMSO control vs. mafosfamide, 100 % vs. 49 ± 
3% (A549), p < 0.001, 100% vs. 45 ± 2% (SF767), p<0.005). Treatment with ALDH3A1 
inhibitors A10, A20, A21, CB7, A64, A70, B37 and B27 had little effect on cell prolifer-
ation (Figure 30A and 30B, grey bars) as single agents. At doses that inhibited 
ALDH3A1 in cell lysates (10 µM), we did not observe significant cytotoxicity in either 
A549 or SF767 cells (p<0.005). We tested doses as high as 50 µM and did not see signif-
icant cytotoxicity in the absence of mafosfamide (p<0.005). Co–treatment of cells with 
10 μM compounds A20, A21, A64, A70, B37 and B27 increased sensitivity to 
mafosfamide in SF767 and A549 cell lines (Figure 30A and 30B). Compound A10 was 
cell line dependent and exhibited some cytotoxicity in A549 cells and seemed to enhance 
mafosfamide sensitivity in CCD13Lu cell line (Figure 30C). We further performed a 
dose–dependent study for the three most potent compounds for sensitization toward 
mafosfamide in A549 and SF767 cells. We used the parent compound, CB7 as well as 
analogs A64 and A70 for our study. We observed a dose–dependent decrease in cell pro-
liferation (Figure 31) as the concentration of compounds CB7, A64 and A70 increase.  
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Figure 30. Chemosensitivity experiments in cancer cells with CB7 analogs. Cells 
were simultaneously treated with mafosfamide (MF) in combination with ALDH3A1 in-
hibitors (10 µM). (A) A549 and (B) SF767 cells treated with mafosfamide (125 µM) for 
19 hours. (C) CCD13Lu cells treated with 40 µM mafosfamide for 19 hours. Cell prolif-
eration was determined using the MTT assay. The DMSO concentration was limited to 
0.25% (v/ v). The p values were calculated by comparing the cellular proliferation of 
mafosfamide treated cells to that of mafosfamide in combination with ALDH3A1 inhibi-
tor treated cells (*, p ≤ 0.001, n = 10–15) or DMSO treated cells to that of compound 
treated cells (**, p ≤ 0.005, n = 10–15). Black bars represent compound treatment alone 
and grey bars represent compound and mafosfamide treatment. Each bar represents the 
mean value ± SE. 
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Figure 31. Dose dependent study with CB7 analogs. A549 and SF767 cells treated 
with increasing concentrations of CB7, A64, and A70 in the presence or absence of 125 
and 150 µM mafosfamide respectively. The p values were calculated by comparing the 
cellular proliferation of mafosfamide treated cells to that of mafosfamide in combination 
with ALDH3A1 inhibitor treated cells (*, p ≤ 0.001, n = 10–15) or DMSO treated cells to 
that of compound treated cells (**, p ≤ 0.005, n = 10–15).  
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IV. Discussion 
Drug resistance is one of the major causes of therapeutic failure during cancer 
treatment. Some of the important mechanisms include altered rate of drug import or ex-
port, target mutation, gene amplification, increased DNA repair and increased expression 
of drug metabolizing enzymes. As one of the major contributors to drug resistance, drug 
metabolizing enzymes are attractive targets for reversing such resistance (Swanson et al., 
2010). Cyclophosphamide is an oxazaphosphorine prodrug used in the treatment of a 
spectrum of cancers but its clinical utility is often limited by bone marrow toxicity as 
dosages are increased to overcome resistance in tumors. Cyclophosphamide forms an in-
termediate known an aldophosphamide when activated by cytochrome P450. By under-
going a non–enzymatic beta–elimination reaction, aldophosphamide forms phospho-
ramide mustard which is the DNA–alkylating agent that targets rapidly dividing cells. 
ALDH isoenzymes and ALDH1A1, in particular, are known for their ability to confer 
resistance to derivatives of cyclophosphamide. The contribution of ALDH3A1 toward 
cyclophosphamide resistance is more controversial, with some studies supporting a role 
and others refuting (Moreb et al., 2007; Ganaganur et al., 1994; Sreerama and Sladek 
1995; Sladek, 1999; Moreb et al., 2005; Giorgianni et al., 2000). We have previously 
shown that non–selective covalent inhibitors of ALDH family members can sensitize 
A549 cells to the cytotoxic effects of aldophosphamide (Khanna et al., 2011), which is 
consistent with earlier studies in which siRNA knockdown of both ALDH1A1 and 
ALDH3A1 were required for maximal sensitivity to aldophosphamide (Moreb et al., 
2007). What is clear from both in vitro and cell–based work is that ALDH1A1 exhibits 
greater catalytic efficiency toward aldophosphamide than ALDH3A1, although the au-
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thors of one study indicated that the purified recombinant enzyme (identical to that used 
in these studies) exhibited “considerable activity” toward aldophosphamide (Giorgianni 
et al., 2000). These authors also concluded that only upon high level of expression, does 
ALDH3A1 play a significant role in conferring resistance to derivatives of cyclophos-
phamide (Giorgianni et al., 2000), something that both A549 and SF767 cells exhibit. 
Consequently, identification of cell permeable selective inhibitors for ALDH3A1, and/ or 
ALDH1A1, may provide a means to understand their individual contributions toward 
aldophosphamide metabolism and potentially widen the therapeutic window during 
treatment regimens that could be individually targeted according to the levels of these 
two ALDH family members.  
In addition to aldehyde oxidation, aldehyde dehydrogenases are known to cata-
lyze the hydrolysis of para–nitrophenylacetate (Sidhu et al., 1975). Competition assays 
have also shown that ester hydrolysis occurs at the aldehyde binding site (Sidhu et al., 
1975). In spite of sharing the same catalytic site for catalysis, the mechanism of reaction, 
however, varies. In the case of ALDH2, aldehyde oxidation involves a nucleophilic reac-
tion of the substrate with active site Cysteine (Cys302) resulting in formation of a thio-
hemiacetal. This is followed by hydride transfer to NAD
+
 yielding a thioester intermedi-
ate and NADH. The thioester is eventually hydrolyzed to the carboxylic acid product in a 
reaction that involves activation of water by an adjacent glutamate (Glu268). The esterase 
activity is stimulated by cofactor NAD
+
, but the co–factor is not essential for the reaction. 
Reaction is initiated by nucleophilic attack on the carbonyl carbon of the substrate by 
Cys302, forming an intermediate thioester and subsequently releasing the corresponding 
alcohol by hydrolysis of the intermediate through activation of water by Glu268 (Mann et 
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al., 1999). Interestingly, kinetic and mutagenic studies in class 3 human stomach alde-
hyde dehydrogenase showed that NAD
+ 
binding had inhibitory effect on the esterase ac-
tivity of stomach ALDH3 but had an activating effect on ALDH2 based esterase activity 
(Mann et al., 1999). Despite having differential effects for NAD
+
 on esterase activity, the 
fact that dehydrogenase and esterase reactions share the same catalytic site and same res-
idues of ALDH for their respective reactions provides us evidence enough that these two 
assays can be used for inhibitor screen and validation. Previous experience in high–
throughput screening from our lab has shown that NADH based absorbance at 340 nm 
wavelength shows absorbance and fluorescence overlap with many compounds in the 
screening library leading to false results. Therefore, we chose to use an esterase based 
assay (λ= 405nm) for our screen that has minimum overlap with the absorbance proper-
ties of the compounds in the library.  
Our initial round of screening provided us with 436 compounds that had >60% 
inhibition of esterase activity. Out of all these compounds, only 71 compounds repro-
duced inhibition of esterase activity in our second round. We bought these 71 compounds 
from commercial vendors and tested them for dehydrogenase (second) assay. Only 55 
inhibited dehydrogenase activity of ALDH3A1. Some of these compounds had structural 
similarity with each other. But an interesting thing to note was that many of our hits 
showed inhibition to both ALDH3A1 and ALDH1A1 activity having minimal to almost 
no effect on ALDH2 activity. We see this trend possibly due to structural similarity be-
tween ALDH1A1 and ALDH3A1 in their active site. Interestingly, two compounds, 
namely CB7 and CB29 were the most selective inhibitors for ALDH3A1 activity. 
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A. Characterization of CB29 binding 
Our steady state kinetic experiments showed that CB29 displays a competitive in-
hibition pattern toward both aldehyde and coenzyme substrates, suggesting that the com-
pound can bind to both the free enzyme and the enzyme–coenzyme species along the re-
action pathway. Our kinetic data is further supported by crystallographic data where we 
see CB29 binding in the aldehyde binding pocket. We can clearly see that the binding of 
aldehyde substrate requires that the inhibitor is displaced in order for the aldehyde to bind 
in a position conducive to catalysis. With respect to the mode of interaction with the co-
enzyme (NADP
+
) species, earlier studies have shown that the coenzyme molecule in 
ALDH isoenzymes undergoes an isomerization event during catalysis with a minimum of 
two conformations for the coenzyme, referred to as the “hydride transfer” and “hydroly-
sis” conformations (Perez Miller et al., 2003). The mode of binding displayed by CB29 
likely requires that it bind to ALDH3A1 when the coenzyme is in the “hydrolysis” con-
formation, since the methyl sulfonyl moiety lies very close to catalytic cysteine and 
would overlap with the position of the nicotinamide ring when it adopts the hydride trans-
fer conformation (Figure 32A). This explains why CB29 is competitive to NADP
+
 bind-
ing as well. Based on this binding pattern, we propose a model for CB29 as shown below 
(Figure 32B). 
Our SAR study showed that ALDH3A1 cannot tolerate larger substituents at the 
R1 position without decreasing inhibitory potency [B5, B18, B22, B6]. We see this trend 
due to steric clashes that would occur with the side chains of Leu119, Tyr412 and Phe401 
in this region. Our SAR study further showed that substitution of the linking amine group 
in CB29 (IC50 16 μM) with an ether linkage is deleterious to potency (IUSC–12417; IC50 
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>100 μM) (Table 3B). The deleterious nature of substituting an ether linkage for this 
amino linkage in CB29 is possibly due to the loss of a hydrogen bonding interaction with 
the peptide carbonyl group of Glu61 or due to the difference in bond distance and angle 
geometries of the respective atoms, or a combination of both. Our SAR data further 
showed that acetamide at the para position of aniline although was not greatly crucial for 
the potency of CB29 but played an important role in terms of ALDH3A1 selectivity. We 
saw when acetamide was substituted with larger amides such as isobutyramide (B13) or 
isopentanamide (B16), these compounds (B13 and B16, respectively) demonstrated 
greater inhibition towards both ALDH1A1 and ALDH3A1. Analogs that have bigger am-
ides at the para position of aniline and larger substitutions at the R1 position (B22) 
showed greater selectivity towards ALDH1A1 than ALDH3A1 at 100 µM. We will re-
quire crystal structure of ALDH1A1 complexed to these compounds to explain this selec-
tivity pattern. However, this information at least provides us a starting point for the de-
velopment of selective inhibitors of ALDH1A1. In addition, our crystal structure showed 
that substituents on the nitrobenzene ring contribute to hydrogen bond, while the latter 
half of the molecule contributes to hydrophobic interactions (Figure 19). Based on these 
results, we propose that further enhancements toward new more potent compounds 
should exploit potential hydrogen bonding interactions with the side chains of Asn118, 
Gln122, and His413, which would create a more even distribution of hydrogen bonding 
interactions.  
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Figure 32. (A) CB29 preventing the formation of hydride transfer conformation. 
The active site of ALDH3A1 with bound CB29 into which the two commonly observed 
conformations of coenzyme have been modeled based on a structural alignment of 
ALDH3A1 with the active site of ALDH2 in which dual conformations of coenzyme are 
observed (RCSB code 1o00). The conformation of Cys243 induced by the binding of 
CB29 to ALDH3A1 is incompatible with either the hydride–transfer conformation of co-
enzyme (1.53 Å between the Sulfur of Cys243 and the C4 position of NAD
+
) or the hy-
drolysis conformation of the coenzyme (2.14 Å between the Sulfur atom of Cys243 and 
the carboxyamide oxygen of NAD
+
). 
 
Nicotinamide 
(Hydrolysis) 
Nicotinamide 
(Hydride–transfer) 
C243 
CB29 
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Figure 32. (B) Kinetic mechanism of CB29 binding. The reaction initiates with NADP
+
 
binding into the Rossmann fold subsequently followed by the binding of benzaldehyde. 
This is followed by thiohemiacetal formation, hydride transfer, hydrolysis and carboxylic 
acid formation. CB29 competes with binding of both aldehyde and NADP
+
. 
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B. Selectivity of CB29 for ALDH3A1 versus ALDH1A1 and ALDH2 
We compared the structure of CB29 to the list of all the reported inhibitors of 
ALDH family for defining isozyme selectivity. A highly selective reversible inhibitor of 
ALDH2, CVT–10216, which is an analog of daidzin, looked particularly interesting be-
cause its methyl–sulfonyl moiety linked to an aniline group resembles that of CB29 (Fig-
ure 33A) (Overstreet et al., 2009). As a structure of human ALDH2 with CVT–10216 is 
not yet available, we examined the human ALDH2 structure with bound to daidzin (PDB 
accession code 2vle) to compare its mode of binding to that of CB29 (Figure 33B). Dai-
dzin binds to ALDH2 via its planar isoflavone ring (Figure 33A, shown in blue) that 
forms an extensive van der Waals contact with Phe170, Trp177, Phe296 and Phe459 in 
the central region of the substrate binding pocket (Figure 33C) (Lowe et al., 2008). The 
phenolic hydroxyl moiety does not form a direct hydrogen bond with the protein; rather it 
forms a hydrogen bond with an ordered water molecule which is, in turn, hydrogen–
bonded to Glu268, the general base residue important for catalysis. The solvent exposed 
glucosyl moiety at the opposing end of daidzin is not greatly critical for selectivity since 
several substitutions at this position were still highly selective and potent for ALDH2 
(Lowe et al., 2008). Overall it seems like the planar isoflavone ring accounts for ALDH2 
selectivity. CVT–10216 maintains the same central isoflavone ring, but substitutes a me-
thylsulfonylamino group in place of the hydroxyl on the benzene ring (Figure 33). Based 
on the ALDH2–daidzin structure, it is difficult to imagine how the methylsulfonylamino 
group can be accommodated within the active site without structural rearrangement. As 
large scale motions of the active site in ALDH2 have not been observed to date, we pro-
pose that CVT–10216 slides back away from Glu268 such that the sulfonyl group in 
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CVT–10216 can now interact with the active site cysteine loop in a manner similar to the 
sulfonyl group in CB29. However, the additional amino group between the aromatic ring 
and the sulfonyl moiety is necessary in CVT–10216 to bring the sulfonyl oxygens within 
hydrogen bonding distance of the peptide nitrogen in this loop. If these sulfonyl groups 
interact similarly, as we propose, what accounts for the highly selective nature of their 
respective interactions in ALDH3A1 and ALDH2? We believe it is the differences in the 
topologies of their respective substrate binding sites. The site in ALDH3A1 is narrow and 
curved through its middle region while that of ALDH2 is largely a straight cylinder with 
similar proportions throughout. Thus, the single bond linkage between the aromatic rings 
in daidzin and CVT–10216 are optimal for the cylindrical site in ALDH2, while the ami-
no linker and the rotations made possible by these two single bonds between the aromatic 
rings in CB29 are optimal for the narrower and curved nature of the ALDH3A1 site but 
not for cylindrical pocket of ALDH2 (Figure 33D).  
In order to understand the specificity of CB29 for ALDH3A1 over ALDH1A1, 
we examined the substrate–binding site of sheep liver ALDH1A1 (PDB accession code 
1bxs). The substrate binding cleft in human ALDH1A1, based on sheep ALDH1A1 struc-
ture, is much larger than either that of ALDH3A1 or ALDH2 (Figure 33E). The enlarged 
substrate site in ALDH1A1 is primarily due to the substitution of Phe459 by Val and 
Met124 by Gly. We believe that this large substrate binding site would form fewer favor-
able contacts with CB29 than those observed in ALDH3A1, which has a relatively nar-
row pocket (Figure 33E). However, analogs of CB29 such as B13, B16, B19, B22 and 
IUSC–12416 with larger substituents at the R1 and R2 positions were inhibitory towards 
ALDH1A1 activity. We believe we see this trend because analogs with larger substitu-
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tions at R1 and R2 positions fill this larger substrate–binding site of ALDH1A1 and pos-
sibly form new productive interactions with ALDH1A1 which stabilize these compounds.  
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(A) 
 
(B) 
 
Figure 33. Selectivity of CB29 for ALDH3A1 against ALDH1A1, ALDH2. (A) Struc-
ture of daidzin and its analog CVT–10216. Blue region shows the common planar isofla-
vone ring. (B) CB29 (sky–blue) bound with in the catalytic pocket of ALDH3A1.  
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(C) 
 
(D) 
 
Figure 33. Selectivity of CB29 for ALDH3A1 against ALDH1A1, ALDH2. (C) Dai-
dzin (yellow) bound within the cylindrical pocket of ALDH2. (D) Position of CB29 with-
in the ALDH2 substrate site based on superimposition of the ALDH3A1 and ALDH2 
structure (RCSB code 1O00). This figure shows the potential steric clashes that could oc-
cur between CB29 (sky–blue) and the ALDH2 substrate site.  
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(E) 
 
 
Figure 33. Selectivity of CB29 for ALDH3A1 against ALDH1A1, ALDH2. (E) Posi-
tion of CB29 within the sheep ALDH1A1 substrate site based on superimposition of the 
ALDH3A1 and sheep ALDH1A1 (RCSB code 1BXS) structures. This view shows the 
larger available space for CB29 (sky–blue) within the ALDH1 active site. 
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C. Characterization of CB7 binding 
Steady state competition experiments have shown that CB7 exhibits a competitive 
mode of inhibition with respect to benzaldehyde with a Ki of 0.1 μM and non–
competitive mode of inhibition with respect to NADP
+
 with a Ki of 0.1 μM. This is con-
sistent with our crystallographic evidence since we saw binding of CB7 in the presence of 
NAD
+
, which is an analog of NADP
+
 (Figure 21B).  
Based on this binding pattern, we propose a model for CB7 as shown below (Figure 
34). The general catalytic mechanism of ALDH involves initial binding of NAD(P)
+
 fol-
lowed by the binding of aldehyde. Based on our steady state kinetics, we propose that 
ALDH3A1 initially binds to NADP
+
 to form E–NADP+ complex. Since, CB7 is non–
competitive to NADP
+
, this complex formation is not interrupted by CB7. The next step 
is the formation of E–NADP+–Aldehyde complex. This complex formation is interrupted 
by CB7 since it is competitive to aldehyde binding. The binding can be reversed by using 
higher concentration of aldehyde that displaces CB7 away from the active site. This is 
subsequently followed by a product release step (carboxylic acid followed by NADPH). 
Our SAR studies on the available analogs of CB7 showed that our original hit com-
pound, CB7, was the most potent. To put this SAR into context, we used the structural 
information available from CB7–ALDH3A1–NAD+ crystal structure. The proximity of 
the benzyl substituent of the benzimidazole moiety to Cys243, Phe401, Leu119 and 
Tyr115 explains the detrimental effects of adding substituents to the R2 and R3 positions 
(Table 4, figure 20 and figure 22). Moreover, the nicotinamide carbonyl oxygen is 3.9 Å 
from the benzimidazole ring such that a methyl group at the R2 position would create ste-
ric overlap with this portion of the NAD
+
 molecule. In addition, the side chain of Tyr65 
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influences substitutions at the R1 and R4/R8 positions, where larger substituents create a 
steric clash with Tyr65. In addition, Tyr115 also impacts the available space surrounding 
the ortho R4/R8 positions. On the other hand, substitutions at the R5 and R6 positions 
were tolerated because of the small cavity between Trp233 and Tyr65. Our SAR study 
also suggests that smaller substitutions, preferably electron withdrawing halogens, were 
optimal at the R6 position. This is likely due to the presence of Trp233 at a distance of 4 
Å and Met237 at a distance of 3.5 Å from the R6 position. Overall, our SAR data was 
fully supported by our structural data and explained why CB7 was the most potent of the 
series and why substitutions at various positions were detrimental to binding. 
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Figure 34. Mechanism of CB7 inhibition. The reaction initiates with NADP
+
 binding 
into the Rossmann fold subsequently followed by the binding of benzaldehyde. This is 
followed by thiohemiacetal formation, hydride transfer, hydrolysis and carboxylic acid 
formation. CB7 competes with aldehyde binding showing no effect on NADP
+
 binding.
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D. Probing CB7 binding of ALDH3A1 site using Q122A and Q122W mutants 
We compared the crystal structure of human ALDH3A1 against two other closely 
related isozymes human ALDH2 and ALDH1A1 from sheep (Figure 35) to compare their 
active site. Upon structural alignment, we identified one important residue, tryptophan 
that is present in both ALDH1A1 and ALDH2 active site but not in ALDH3A1. In the 
ALDH3A1 active site, a glutamine residue is present in the position corresponding to 
tryptophan. In order to investigate how much contribution glutamine makes in CB7 bind-
ing, we decided to mutate glutamine to either alanine or tryptophan. Kinetic parameters 
(Kcat, Km, Kcat/ Km) were determined for benzaldehyde and propionaldehyde oxidation for 
mutants and wild type ALDH3A1 (Table 8). Ki was further determined for CB7 against 
Q122A, Q122W and wild type ALDH3A1 as well (Table 8). Results showed that the ala-
nine mutation did not show a drastic effect on enzyme’s turnover rate of benzaldehyde 
(4.91 µM
-1 
min
-1
 for wild type ALDH3A1 and 3.2 µM
-1 
min
-1
 for Q122A mutant) and 
propionaldehyde (0.05 µM
-1 
min
-1
 for wild type ALDH3A1 and 0.049 µM
-1
min
-1
 for 
Q122A mutant). The Ki value for CB7 binding was also unchanged (Ki = 0.2 µM for WT 
enzyme and Q122A). However, when glutamine was mutated to tryptophan, CB7 was not 
inhibitory at all to Q122W activity up to 250 µM concentration. The turnover rate of ben-
zaldehyde decreased 3 fold (1.7 µM
-1 
min
-1
) as compared to the rate of wild type enzyme 
whereas that for propionaldehyde was 80% (0.039 µM
-1 
min
-1
) of the rate of wild type 
enzyme. This data clearly supported the idea that glutamine was the major amino acid 
that was responsible for imparting selectivity to CB7.  
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Figure 35. Structural alignment of sheep ALDH1A1, ALDH2 and ALDH3A1. Cata-
lytic surface of ALDH3A1 is shown in pink color. ALDH1A1, ALDH2 and ALDH3A1 
are represented is sky blue, yellow and pink color respectively. The figure shows that 
ALDH3A1 has a glutamine at 122 position instead of tryptophan, which is present in 
ALDH2 and sALDH1A1. 
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Table 8. Catalytic activity of WT ALDH3A1, Q122A and Q122W. Structural compar-
ison showed that ALDH3A1 has a glutamine at 122 position instead of tryptophan, which 
is present in ALDH2 and sALDH1A1. Two mutations (Q122A and Q122W) were intro-
duced at this position to study their kinetic properties. 
 
  Benzaldehyde Benzaldehyde CB7 Propionaldehyde 
  Km Kcat/ Km Ki Kcat/ Km 
  (µM) Min
-1
 µM
-1
 (µM) Min
-1
 µM
-1
 
wt 279 ± 23  4.91 ± 0.25 0.2 0.05 ± 0.003 
Q122A 425 ± 38 3.2 ± 0.13 0.2 0.049 ± 0.003 
Q122W 257 ± 35 1.73 ± 0.27 NI 250 µM)  0.039 ± 0.005 
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E. Sensitization toward mafosfamide 
Several of the selective inhibitors of ALDH3A1 reported here enhance the anti–
proliferative effects of mafosfamide in SF767 cells, which express only ALDH3A1, as 
well as in A549 cells which express both ALDH1A1 and ALDH3A1. The enhancements 
increase in a dose–dependent manner in SF767 cells with CB29 analogs, where 
ALDH3A1 is the sole target (Figure 29E). In the case of CB7 analogs as well, we see a 
dose dependent increment in mafosfamide sensitivity both in A549 and SF767 cells (Fig-
ure 31). In our hands, the antibodies utilized for detection of ALDH1A1 also detect 
ALDH1A2, ALDH1A3, ALDH1B1, and ALDH2 (Figure 25C), therefore SF767 appears 
devoid of all ALDH1 subtypes, as well as ALDH2, giving us a good model system to 
study the contribution of ALDH3A1 to mafosfamide resistance.  
In the case of CB29 analogs, the dose–response in SF767 cells matches reasona-
bly the in vitro IC50 data in which both assays produced values between 15 and 50 µM 
(Table 3A, 3B and Figure 29E). The data presented here suggest that ALDH3A1 can 
make a substantial contribution to detoxication of derivatives of cyclophosphamide, even 
in the face of competing enzymes, such as ALDH1A1. These data are consistent with the 
siRNA studies where knockdown of both ALDH1A1 and ALDH3A1 was required for 
maximal sensitivity toward mafosfamide (Moreb et al., 2007). 
Cell based chemosensitivity experiments conducted with CB7 analogs show a 
similar phenotypic effect in A549 and SF767 cells. Even though the dose–responses were 
in the lower micromolar range (5–7.5 μM), nearly 20 fold higher than its IC50 values, the 
fact that we see the effect in a much lower concentration than the analogs CB29 (15–50 
μM range) makes us believe that we are targeting ALDH3A1. It is also supported by the 
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fact that the CB7 class is highly potent and thus would be expected to require lower con-
centrations than the CB29 class for cellular efficacy. The variability in concentration be-
tween in vitro kinetics versus cell based assays could be affected by other factors such as 
membrane permeability, cellular metabolism and high concentration of competing alde-
hydes inside the cells.  
One interesting result that we observed in our study was that SF767 cells were 
sensitized more to CB7 analogs as compared to A549 cell lines. This is likely due to the 
co–expression of ALDH1A1 and ALDH3A1, both of which contribute to chemo-
resistance for mafosfamide, whereas SF767 only expresses ALDH3A1. Hence, inhibition 
of ALDH3A1 still leaves the alternative pathway for mafosfamide metabolism active in 
A549 cells. In order to see even a higher chemosensitivity in A549 cells, a proper strate-
gy would be to use both ALDH1A1 and ALDH3A1 selective inhibitors. Since SF767 
cells have no ALDH1A1 expression, using ALDH3A1 inhibitors achieves maximum 
mafosfamide sensitivity. Our experiments also showed that normal lung cells (CCD13Lu) 
did not show any detectable expression of ALDH1, ALDH2 and ALDH3A1 isozymes. 
These cells also had a lower ED50 value for mafosfamide (40 μM). However, when nor-
mal lung cells become tumorigenic, they show much higher expression of ALDH1A1 and 
ALDH3A1, and their ED50 value for mafosfamide increases by almost 3.25 fold (125 
μM). Variable ED50 values and protein expression patterns of ALDH isozymes in normal 
versus tumorigenic cells makes an important point that ALDH isozymes could be in-
volved in such a high degree of chemoresistance. Also, since normal lung cells 
(CCD13Lu) were not affected by 10 μM concentrations of CB7 and most analogs, we 
infer that these inhibitors target ALDH3A1 activity to inhibit cell proliferation in A549 
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and SF767 cells. These inhibitors were also not able to increase the chemosensitivity to 
mafosfamide in CCD13Lu cells, which again supports our hypothesis that ALDH3A1 
inhibitors can be used to increase chemosensitivity in ALDH3A1 positive cells.  
 
F. Comparison of catalytic site of ALDH1A1, ALDH2 and ALDH3A1 
Even though earlier studies have identified inhibitors that target ALDHs in gen-
eral, having isozyme selective inhibitors would be helpful in studying functions of indi-
vidual enzymes. Structural comparisons of catalytic sites have shown distinct structural 
features of three important enzymes ALDH1A1, ALDH2 and ALDH3A1 as shown in 
Figure 36. ALDH1A1 has a funnel shaped catalytic site. ALDH2 has a cylindrical shaped 
catalytic site whereas ALDH3A1 unlike ALDH2 has a curved shaped opening in its cata-
lytic site. The pocket is narrow at its outer opening and broader inside (Figure 36). This 
structural diversity would provide us an advantage for the development of selective inhib-
itors for each of these isozymes. Provided that we know the structural properties of these 
three enzymes, having regulators that govern their functions would provide us with an 
additional advantage to study them individually. 
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Figure 36. Active site comparison of ALDH1A1, ALDH2 and ALDH3A1. Compari-
son of the active site of ALDH1A1, ALDH2 and ALDH3A1 
 
Since many exogenously administered drugs are active in their aldehyde form, 
identification of isozyme selective inhibitors for various ALDH isozymes will help us 
investigate their individual contributions toward drug metabolism. It will also help us un-
derstand the individual contribution of different forms of ALDH towards metabolism of 
numerous cytotoxic aldehydes, including those linked to cellular differentiation, detoxi-
cation of peroxidic aldehydes, as well as metabolism of neurotransmitters. In this study, 
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we characterized two selective inhibitors of ALDH3A1, an enzyme implicated in aldo-
phosphamide metabolism. Even though, the catalytic efficiency of ALDH3A1 is 1/ 7
th
 
than that of ALDH1A1 for aldophosphamide (Giorgianni et al., 2000), the expression 
levels in some cancer cell lines are such that an impact on aldophosphamide metabolism 
cannot be ignored. Indeed, some cells such as the (SF767) glioblastoma cell line only ex-
press ALDH3A1 and have ED50 values similar to those cells in which both enzymes are 
expressed in similar levels (A549). Therefore, selective ALDH3A1 inhibitors are useful 
tools that can be used to manipulate the contributions of ALDH3A1 toward aldophos-
phamide metabolism, as well as other biologically relevant aldehydes.  
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V. Future Directions 
Our study has helped us identify two classes of compounds that selectively inhibit 
ALDH3A1 activity. Some of the analogs did not exhibit great phenotypic properties pos-
sibility due to poor permeability or stability. At this point, we do not know what makes 
these inhibitors permeable or stable. Fortunately, we have altogether six important ana-
logs (B4, B9, CB29, CB7, A64, A70) that exhibit promising phenotypic property in cells 
based studies. An interesting follow up study would be to conduct a pharmacokinetic and 
pharmacodynamic study with these compounds by testing them in mice. We would be 
interested in knowing how much of these compound can be administered to mice, which 
are the ones with least toxicity and what would be the optimal route for administration. 
We would also like to know the half–life and the rate at which these compounds are elim-
inated from the body. If successful, compounds with optimal pharmacokinetic and phar-
macodynamic properties would further be tested in tumorigenic mouse models to see 
their effect along with cyclophosphamide in treating resistant forms of lung adenocarci-
nomas and glioblastoma. 
These two scaffolds can also be used as tools to study the contribution of 
ALDH3A1 in cellular function. One important approach would be to develop a covalent 
inhibitor of ALDH3A1 by using the CB29 scaffold. The methyl carbon attached to sul-
fonyl group lies at an approximate distance of 4.2 Å away from the active site sulfur 
(Cys302) (Figure 37). Since Cysteine is a nucleophile, this property can be exploited to 
create covalent inhibitors of ALDH3A1. The analogs that could possibly bind to 
ALDH3A1 covalently with their possible reaction mechanism are shown below (Figure 
38).  
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Figure 37. Structure based design of covalent inhibitors. Figure showing the immedi-
ate distance (4.2Å) between methyl carbon (attached to sulfonyl sulfur) and sulfur from 
Cys302 that can be exploited for making covalent inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Possible mechanism of action. List of possible analogs that can exhibit a 
SN2 mechanism based covalent modification of ALDH3A1. 
Nucleophilic substitution (SN
2
 mechanism) 
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For example, if we specifically want to completely knockdown ALDH3A1 activi-
ty (just like by using siRNA), these covalent inhibitors can be important tools since they 
do not inhibit ALDH1A1 or ALDH2 activity. In addition, CB7 can also be used as a 
chemical tool to study the contribution of ALDH3A1 in metabolism of various exoge-
nous and endogenous aldehydes.  
 Besides ALDH3A1, there are several other ALDH3 isoforms such as ALDH3A2, 
ALDH3B1, ALDH3B2, which are not characterized for their functions. Mutation in 
ALDH3A2 is implicated in Sjogren–Larson syndrome whereas ALDH3B1 is implicated 
in schizophrenia. Compounds identified in this study can be used as starting scaffolds for 
designing inhibitors for these other enzymes that are closely related to ALDH3A1.  
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